[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 3468
1. Uche A: Pantoea agglomerans bacteremia in a 65-year-old man with acute myeloid leukemia: case report and review. South Med J; 2008 Jan;101(1):102-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pantoea agglomerans bacteremia in a 65-year-old man with acute myeloid leukemia: case report and review.
  • A 65-year-old man with a recent history of acute leukemia was admitted with complaints of chills and rigors.
  • He had a long-standing Hickman catheter which was removed following the isolation of a gram negative rod later identified as Pantoea agglomerans.
  • [MeSH-major] Bacteremia / epidemiology. Catheters, Indwelling / adverse effects. Gram-Negative Bacterial Infections / etiology. Leukemia, Myeloid, Acute / epidemiology. Pantoea
  • [MeSH-minor] Aged. Humans. Male. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18176303.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 11
  •  go-up   go-down


2. Deng T, Li J, Zhang LL, Jiang JH, Chen JN, Shen GL, Yu RQ: A sensitive fluorescence anisotropy method for the direct detection of cancer cells in whole blood based on aptamer-conjugated near-infrared fluorescent nanoparticles. Biosens Bioelectron; 2010 Mar 15;25(7):1587-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results showed that the fluorescent nanoparticle-tagged aptamer probes sequence could achieve specific recognition of the target cancer cells from complex mixtures including whole blood samples.
  • Moreover, the present fluorescence anisotropy assay technique could be practically utilized for the detection of acute leukemia samples with improved capabilities and be comparable to the immunophenotyping methods clinically used.
  • [MeSH-major] Aptamers, Nucleotide. Leukemia / pathology. Nanoparticles. Neoplastic Cells, Circulating / pathology. Spectrometry, Fluorescence / methods. Spectroscopy, Near-Infrared / methods
  • [MeSH-minor] Anisotropy. Cell Line, Tumor. Humans. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Elsevier B.V. All rights reserved.
  • (PMID = 20022484.001).
  • [ISSN] 1873-4235
  • [Journal-full-title] Biosensors & bioelectronics
  • [ISO-abbreviation] Biosens Bioelectron
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aptamers, Nucleotide
  •  go-up   go-down


3. Kulshrestha R, Sah SP: Pattern of occurrence of leukemia at a teaching hospital in eastern region of Nepal - a six year study. JNMA J Nepal Med Assoc; 2009 Jan-Mar;48(173):35-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of occurrence of leukemia at a teaching hospital in eastern region of Nepal - a six year study.
  • INTRODUCTION: Pattern of leukemia is known to vary widely throughout the world.
  • The characterization of distribution patterns of different subtypes of leukemia in Nepal needs further study.
  • We wanted to study the leukemia pattern in our institute.
  • METHODS: A retrospective study of 196 cases of leukemia, diagnosed at BPKIHS, between January 1997 to December 2002 was done.
  • We analyzed the pattern of leukemia at BPKIHS by morphological subtype, gender, age at diagnosis, time period of diagnosis (seasonality), and geographic distribution.
  • RESULTS: Morphological sub typing showed that 121 cases were of acute leukemia and 75 of chronic leukemia.
  • Chronic myeloid leukemia constituted the single largest group comprising 35.2 % of all cases, followed by acute myeloid leukemia (28.57 %) and acute lymphoid leukemia (19.9 %).
  • This is the second series of leukemia from Nepal.
  • CONCLUSIONS: The data published in this study reflects the leukemia pattern in the eastern region of Nepal.
  • [MeSH-major] Hospitals, Teaching / statistics & numerical data. Leukemia / epidemiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19529056.001).
  • [ISSN] 0028-2715
  • [Journal-full-title] JNMA; journal of the Nepal Medical Association
  • [ISO-abbreviation] JNMA J Nepal Med Assoc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


Advertisement
4. Li ZJ, Chen ZX, Cen JN, Lu J, He J: [Establishment of a nude mouse model of human monocytic leukemia with multi-organ infiltration]. Ai Zheng; 2006 Oct;25(10):1307-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of a nude mouse model of human monocytic leukemia with multi-organ infiltration].
  • BACKGROUND & OBJECTIVE: Acute leukemia is always accompanied by extramedullary infiltration, which may be the source of relapse.
  • [MeSH-major] Disease Models, Animal. Leukemia, Monocytic, Acute / pathology. Leukemic Infiltration / pathology
  • [MeSH-minor] Animals. Antigens, CD45 / metabolism. Bone Marrow Cells / metabolism. Cell Line, Tumor. Kidney / pathology. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Stomach / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17059783.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.1.3.48 / Antigens, CD45
  •  go-up   go-down


5. Mizushima Y, Taki T, Shimada A, Yui Y, Hiraumi Y, Matsubara H, Watanabe M, Watanabe K, Kamitsuji Y, Hayashi Y, Tsukimoto I, Kobayashi R, Horibe K, Tawa A, Nakahata T, Adachi S: Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group. Int J Hematol; 2010 Jun;91(5):831-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.
  • High BAALC (brain and acute leukemia, cytoplasmic) gene expression may indicate an adverse prognosis for adults who have acute myeloid leukemia (AML) and a normal karyotype, but its prognostic significance for pediatric AML cases is unclear.
  • [MeSH-major] Asian Continental Ancestry Group / genetics. CCAAT-Enhancer-Binding Proteins. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / diagnosis. Mutation. Neoplasm Proteins


6. Petropoulos K, Arseni N, Schessl C, Stadler CR, Rawat VP, Deshpande AJ, Heilmeier B, Hiddemann W, Quintanilla-Martinez L, Bohlander SK, Feuring-Buske M, Buske C: A novel role for Lef-1, a central transcription mediator of Wnt signaling, in leukemogenesis. J Exp Med; 2008 Mar 17;205(3):515-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Deregulation of this pathway has been linked to a large variety of cancers, including different subtypes of leukemia.
  • Here, we demonstrate Lef-1 expression in murine HSCs as well as its expression in human leukemia.
  • Mice transplanted with bone marrow retrovirally transduced to express Lef-1 or a constitutive active Lef-1 mutant showed a severe disturbance of normal hematopoietic differentiation and finally developed B lymphoblastic and acute myeloid leukemia (AML).
  • Furthermore, single cell experiments and limiting dilution transplantation assays demonstrated that Lef-1-induced AML was propagated by a leukemic stem cell with lymphoid characteristics displaying Ig DH-JH rearrangements and a B220(+) myeloid marker(-) immunophenotype.
  • These data indicate a thus far unknown role of Lef-1 in the biology of acute leukemia, pointing to the necessity of balanced Lef-1 expression for an ordered hematopoietic development.
  • [MeSH-major] Leukemia / etiology. Lymphoid Enhancer-Binding Factor 1 / metabolism. Wnt Proteins / metabolism
  • [MeSH-minor] Animals. Gene Expression. Hematopoiesis / genetics. Hematopoiesis / physiology. Hematopoietic Stem Cell Transplantation. Hematopoietic Stem Cells / metabolism. Humans. Leukemia, Myeloid, Acute / etiology. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Mice. Neoplastic Stem Cells / metabolism. RNA, Messenger / genetics. RNA, Messenger / metabolism. Signal Transduction

  • MedlinePlus Health Information. consumer health - Leukemia.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Immunity. 2000 Jul;13(1):15-24 [10933391.001]
  • [Cites] Cancer Cell. 2006 Nov;10(5):363-74 [17097559.001]
  • [Cites] Blood. 2002 Jul 1;100(1):238-45 [12070033.001]
  • [Cites] Dev Cell. 2002 Jul;3(1):137-47 [12110174.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10008-13 [12105272.001]
  • [Cites] Bioinformatics. 2002;18 Suppl 1:S96-104 [12169536.001]
  • [Cites] Nature. 2003 May 22;423(6938):409-14 [12717450.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 20;101(3):817-22 [14718672.001]
  • [Cites] Genes Dev. 2004 Feb 15;18(4):411-22 [15004008.001]
  • [Cites] J Exp Med. 1997 Feb 17;185(4):653-61 [9034144.001]
  • [Cites] Genes Dev. 1997 Feb 15;11(4):476-91 [9042861.001]
  • [Cites] Immunity. 1998 Jan;8(1):11-20 [9462507.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] Nat Rev Immunol. 2005 Jan;5(1):21-30 [15630426.001]
  • [Cites] Nature. 2005 Apr 14;434(7035):843-50 [15829953.001]
  • [Cites] J Clin Invest. 2005 Aug;115(8):2159-68 [16025155.001]
  • [Cites] Immunity. 2005 Dec;23(6):599-609 [16356858.001]
  • [Cites] Semin Immunol. 2006 Feb;18(1):12-9 [16431127.001]
  • [Cites] J Immunol. 2006 Aug 15;177(4):2294-303 [16887990.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1037-47 [16951686.001]
  • [Cites] Nat Immunol. 2006 Oct;7(10):1048-56 [16951689.001]
  • [Cites] Nat Med. 2006 Oct;12(10):1191-7 [17063141.001]
  • [Cites] Cell. 2006 Nov 3;127(3):469-80 [17081971.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(22):7537-44 [11604490.001]
  • (PMID = 18316418.001).
  • [ISSN] 1540-9538
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LEF1 protein, human; 0 / Lef1 protein, mouse; 0 / Lymphoid Enhancer-Binding Factor 1; 0 / RNA, Messenger; 0 / Wnt Proteins
  • [Other-IDs] NLM/ PMC2275375
  •  go-up   go-down


7. Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, Ries RE, Kapur D, Nagarajan R, Dale DC, Bolyard AA, Boxer LA, Welte K, Zeidler C, Donadieu J, Bellanné-Chantelot C, Vardiman JW, Caligiuri MA, Bloomfield CD, DiPersio JF, Tomasson MH, Graubert TA, Westervelt P, Watson M, Shannon W, Baty J, Mardis ER, Wilson RK, Ley TJ: Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood; 2007 Sep 1;110(5):1648-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.
  • Severe congenital neutropenia (SCN) is an inborn disorder of granulopoiesis.
  • Like most other bone marrow failure syndromes, it is associated with a marked propensity to transform into a myelodysplastic syndrome (MDS) or acute leukemia, with a cumulative rate of transformation to MDS/leukemia that exceeds 20%.
  • In this study, we performed mutational profiling of 14 genes previously implicated in leukemogenesis using 14 MDS/leukemia samples from patients with SCN.
  • The sensitivity and specificity of the sequencing pipeline was validated by determining the frequency of mutations in these 14 genes using 188 de novo AML samples.
  • As expected, mutations of tyrosine kinase genes (FLT3, KIT, and JAK2) were common in de novo AML, with a cumulative frequency of 30%.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Genetic Disorders.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Invest. 1998 Aug 1;102(3):483-92 [9691084.001]
  • [Cites] Haematologica. 2000 Nov;85(11):1207-10 [11064470.001]
  • [Cites] J Exp Med. 1999 Feb 15;189(4):683-92 [9989983.001]
  • [Cites] Acta Paediatr Suppl. 1956 Feb;45(Suppl 105):1-78 [13326376.001]
  • [Cites] Haematologica. 2005 Jan;90(1):45-53 [15642668.001]
  • [Cites] N Engl J Med. 2005 Jan 20;352(3):254-66 [15659725.001]
  • [Cites] Leukemia. 2005 Mar;19(3):329-34 [15674366.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1419-22 [15870172.001]
  • [Cites] Leukemia. 2005 Dec;19(12):2232-40 [16281072.001]
  • [Cites] Blood. 2006 May 15;107(10):3847-53 [16434492.001]
  • [Cites] Blood. 2006 May 15;107(10):4011-20 [16455956.001]
  • [Cites] Leukemia. 2006 Jun;20(6):971-8 [16598306.001]
  • [Cites] J Toxicol Environ Health A. 2000 Nov;61(5-6):381-6 [11086943.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3589-95 [11369655.001]
  • [Cites] Blood. 2002 May 1;99(9):3129-35 [11964274.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4326-35 [12036858.001]
  • [Cites] Blood. 2002 Aug 1;100(3):998-1007 [12130514.001]
  • [Cites] Blood. 2003 Feb 1;101(3):822-6 [12393424.001]
  • [Cites] Genome Res. 2003 May;13(5):954-64 [12695328.001]
  • [Cites] Nat Genet. 2003 Jun;34(2):148-50 [12717436.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1474-9 [12702504.001]
  • [Cites] Blood. 2003 Nov 15;102(10):3850; author reply 3850-1 [14597609.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14275-80 [14614138.001]
  • [Cites] Am J Pathol. 2004 Jan;164(1):305-13 [14695343.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Mar;39(3):217-23 [14732923.001]
  • [Cites] Br J Cancer. 2004 Jul 19;91(2):355-8 [15188009.001]
  • [Cites] J Mol Biol. 1970 Mar;48(3):443-53 [5420325.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Jan;51(1):1-12 [1984836.001]
  • [Cites] Blood. 1993 May 15;81(10):2496-502 [8490166.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4480-4 [7514305.001]
  • [Cites] N Engl J Med. 1995 Aug 24;333(8):487-93 [7542747.001]
  • [Cites] Blood. 1995 Dec 15;86(12):4579-86 [8541548.001]
  • [Cites] Br J Haematol. 1996 Jun;93(3):527-33 [8652369.001]
  • [Cites] Br J Haematol. 1996 Aug;94(2):279-84 [8759887.001]
  • [Cites] Leukemia. 1997 Jan;11(1):120-5 [9001427.001]
  • [Cites] Blood. 1997 Apr 1;89(7):2369-75 [9116280.001]
  • [Cites] Leukemia. 1997 Jul;11(7):1005-8 [9204982.001]
  • [Cites] Genome Res. 1998 Mar;8(3):175-85 [9521921.001]
  • [Cites] Genome Res. 1998 Mar;8(3):186-94 [9521922.001]
  • [Cites] Blood. 1998 Jul 1;92(1):32-9 [9639496.001]
  • [Cites] Leuk Res. 2006 Oct;30(10):1235-9 [16533529.001]
  • [Cites] Blood. 2006 Dec 1;108(12):3654-61 [16912228.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1596-604 [17145595.001]
  • [Cites] Blood. 2007 Jan 1;109(1):93-9 [16985178.001]
  • [Cites] Genome Res. 2007 May;17(5):659-66 [17416743.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2113-9 [15951308.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3747-54 [16109776.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4628-35 [16497969.001]
  • [Cites] Semin Hematol. 2006 Jul;43(3):189-95 [16822461.001]
  • [Cites] Methods Mol Biol. 2000;132:365-86 [10547847.001]
  • [Cites] Blood. 2000 Jan 15;95(2):726-7 [10660321.001]
  • [Cites] Semin Hematol. 2000 Jan;37(1):91-101 [10676914.001]
  • [Cites] Br J Haematol. 2000 Feb;108(2):346-56 [10691865.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2132-7 [10706885.001]
  • [Cites] Blood. 2000 Jul 15;96(2):429-36 [10887102.001]
  • [Cites] Blood. 2000 Oct 15;96(8):2862-9 [11023523.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • (PMID = 17494858.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA101140; United States / NCI NIH HHS / CA / U10 CA031946; United States / NCI NIH HHS / CA / U10 CA101140; United States / NCI NIH HHS / CA / CA101937; United States / NCI NIH HHS / CA / P01 CA101937; United States / NCI NIH HHS / CA / CA31946
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CSF3R protein, human; 0 / Neoplasm Proteins; 0 / Receptors, Colony-Stimulating Factor; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Other-IDs] NLM/ PMC1975847
  •  go-up   go-down


8. Abu-Khalaf MM, Windsor S, Ebisu K, Salikooti S, Ananthanarayanan G, Chung GG, DiGiovanna MP, Haffty BG, Abrams M, Farber LR, Hsu AD, Reiss M, Zelterman D, Burtness BA: Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology; 2005;69(5):372-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One patient developed acute leukemia.
  • Sixty-nine (81%) patients are alive, and 59 (69%) patients are alive and free of distant disease at a median follow-up of 5 years.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Metastasis. Time Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16319508.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30CA16359
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Massimo LM, Wiley TJ, Bonassi S, Caprino D: Longitudinal psychosocial outcomes in two cohorts of adult survivors from childhood acute leukemia treated with or without cranial radiation. Minerva Pediatr; 2006 Feb;58(1):1-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal psychosocial outcomes in two cohorts of adult survivors from childhood acute leukemia treated with or without cranial radiation.
  • AIM: In 1982, 60 children affected by acute lymphoblastic leukemia, treated between 1974 and 1978 with or without cranial radiation, in complete remission, and 2 years at least after stopping therapy, were submitted to a detailed psychological investigation.
  • Most of them did not even know the name of their disease.
  • [MeSH-major] Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Survivors / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16541001.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


10. Li Y, Zhang R, Lu XL, Wang PP, Fan H, Lü XY: [Tryptase relation to VEGF in acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct;13(5):793-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Tryptase relation to VEGF in acute leukemia].
  • In order to investigate the role of tryptase in angiogenesis of acute leukemia (AL), the expressions of tryptase and vascular endothelial growth factor (VEGF) in leukemic cells from 61 patients with AL were examined by using immunocytochemical method, and the correlation between tryptase and VEGF was analyzed.
  • The results showed that tryptase positive expression was found in 15 out of 51 patients with acute myeloid leukemia (AML) (M(1) 1/3, M(2) 7/15, M(3) 5/20, M(5) 2/8).
  • However, none of 10 patients with acute lymphocytic leukemia (ALL) showed tryptase expression.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277844.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vascular Endothelial Growth Factor A; EC 3.4.21.59 / Tryptases
  •  go-up   go-down


11. Jun DY, Kim JS, Park HS, Han CR, Fang Z, Woo MH, Rhee IK, Kim YH: Apoptogenic activity of auraptene of Zanthoxylum schinifolium toward human acute leukemia Jurkat T cells is associated with ER stress-mediated caspase-8 activation that stimulates mitochondria-dependent or -independent caspase cascade. Carcinogenesis; 2007 Jun;28(6):1303-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptogenic activity of auraptene of Zanthoxylum schinifolium toward human acute leukemia Jurkat T cells is associated with ER stress-mediated caspase-8 activation that stimulates mitochondria-dependent or -independent caspase cascade.
  • After the treatment of Jurkat T cells with AUR, the endoplasmic reticulum (ER) stress-mediated activation of caspase-12 and -8 and subsequent apoptotic events including c-Jun N-terminal kinase (JNK) activation, cleavage of FLICE inhibitory protein and Bid, mitochondrial cytochrome c release, activation of caspase-9 and -3, degradation of poly (ADP-ribose) polymerase and apoptotic DNA fragmentation were induced in a dose-dependent manner.
  • The individual or simultaneous addition of the m-calpain inhibitor (E64d), JNK inhibitor (SP600125) and mitochondrial permeability transition pore inhibitor (CsA) failed to prevent apoptotic events including caspase-8 activation and Bid cleavage, unless the caspase-8 inhibitor (z-IETD-fmk) was combined, whereas AUR-induced caspase-12 activation was sustained even in the concomitant presence of z-IETD-fmk.
  • [MeSH-major] Apoptosis / drug effects. Caspase 8 / metabolism. Coumarins / pharmacology. Endoplasmic Reticulum / enzymology. Leukemia-Lymphoma, Adult T-Cell / enzymology. Leukemia-Lymphoma, Adult T-Cell / pathology. Mitochondria / enzymology. Zanthoxylum

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17301064.001).
  • [ISSN] 0143-3334
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coumarins; 495-02-3 / aurapten; EC 3.4.22.- / CASP8 protein, human; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


12. Ravandi F: Role of cytokines in the treatment of acute leukemias: a review. Leukemia; 2006 Apr;20(4):563-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of cytokines in the treatment of acute leukemias: a review.
  • Myeloid growth factors, such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, have been used to decrease the duration of chemotherapy-induced neutropenia and thereby reduce the incidence and severity of infections in various regimens used to treat acute myeloid leukemia and acute lymphoblastic leukemia.
  • These growth factors have also been used to recruit dormant myeloid leukemia cells into the S phase of cell cycle in order to increase their susceptibility to the antileukemic effects of agents such as cytarabine.
  • A reduction in the duration of neutropenia has been the most consistent finding; this has not been associated with stimulation of leukemia cells, the main concern of using this strategy.
  • Unfortunately, few studies have reported a benefit in prolonging the duration of disease-free survival or overall survival.
  • Other cytokines, including interleukins and thrombopoietin, have also been evaluated for their theoretical ability to recruit immune mechanisms to eradicate residual leukemia burden after chemotherapy, and to stimulate platelet production.
  • In this review, we summarize the clinical experience with these growth factors in treating acute leukemias.
  • [MeSH-major] Cytokines / therapeutic use. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Neutropenia / drug therapy. Prospective Studies. Randomized Controlled Trials as Topic. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498390.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines
  • [Number-of-references] 92
  •  go-up   go-down


13. Tamai H, Inokuchi K: 11q23/MLL acute leukemia : update of clinical aspects. J Clin Exp Hematop; 2010;50(2):91-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 11q23/MLL acute leukemia : update of clinical aspects.
  • Rearrangements of the MLL gene located at 11q23 are common chromosomal abnormalities associated with acute leukemia (AL), especially infant and secondary leukemia after previous treatment with DNA topoisomerase II inhibitors.
  • Recent studies showed that the prognosis of 11q23/MLL AL varies widely according to the partner gene, the leukemia cell lineage, the age of the patient and the treatment administered.
  • Special strategies are needed to treat 11q23/MLL AL, including allogeneic hematopoietic stem cell transplantation, according to the fusion partner.
  • The development of novel methodologies, including new molecular therapeutic targets, is also needed to improve the prognosis of 11q23/MLL AL.
  • [MeSH-major] Chromosomes, Human, Pair 11 / genetics. Leukemia / genetics. Myeloid-Lymphoid Leukemia Protein / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21123966.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / MLL protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  •  go-up   go-down


14. Wouters BJ, Koss C, Delwel R: Gene expression profiling for improved dissection of acute leukemia: a recently identified immature myeloid/T-lymphoid subgroup as an example. Blood Cells Mol Dis; 2008 May-Jun;40(3):395-400
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling for improved dissection of acute leukemia: a recently identified immature myeloid/T-lymphoid subgroup as an example.
  • In this concise overview, we discuss recent findings concerning a distinct subgroup of acute myeloid/T-lymphoid leukemia.
  • We describe how we identified these leukemias in multiple cohorts of acute myeloid leukemia (AML) using a combination of gene expression profiling and additional analytic approaches, and how we obtained insight in possible mechanisms leading to their phenotype.
  • [MeSH-major] CCAAT-Enhancer-Binding Proteins / genetics. Gene Expression Regulation, Leukemic. Leukemia, Myeloid, Acute / genetics. Leukemia, Myeloid, Acute / metabolism. Leukemia, T-Cell / genetics. Leukemia, T-Cell / metabolism

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18096415.001).
  • [ISSN] 1096-0961
  • [Journal-full-title] Blood cells, molecules & diseases
  • [ISO-abbreviation] Blood Cells Mol. Dis.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 118316
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCAAT-Enhancer-Binding Proteins; 0 / CEBPA protein, human; 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  • [Number-of-references] 28
  •  go-up   go-down


15. Zhang ZM, Xie ZX, Tan DR, Huang CH: [Detection of glutathione S-transferase and lung resistance-related proteins in acute leukemia and its clinical significance]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Jun;30(3):292-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of glutathione S-transferase and lung resistance-related proteins in acute leukemia and its clinical significance].
  • OBJECTIVE: To explore the relationship among intracellular glutathione S-transferase activity (GST), the expression of lung resistance-related proteins (LRP) in acute leukemia, and its clinical effects.
  • METHODS: The GST activity of bone marrow mononuclear cells and LRP expression in 57 acute leukemia patients were detected by the spectrophotometry assay and immuno-cytochemistry (SABC), respectively.
  • RESULTS: The GST activity of bone marrow mononuclear cells in the acute leukemia group was significantly higher than that of the control group (P < 0.01).
  • The GST activity of mononuclear cells in acute leukemia was positively correlated with the percentage of blast in the bone marrow (r = 0.30, P < 0.05).
  • The GST activity of mononuclear cells in the untreated acute leukemia group was obviously higher than that of the complete remission group (P <0.01).
  • The GST activity in the refractory or relapsed acute leukemia group was significantly higher than that of the complete remission group and untreated leukemia group (P <0.05).
  • In post-chemotherapy 13 of 17 the LRP-positive patients were the non-remission, 12 of the 20 LRP-negative patients were the complete remission.
  • The GST activities of non-remission patients in the LRP-positive and LRP-negative group obviously increased.
  • CONCLUSION: The increase of GST activity in the bone marrow mononuclear cells is related to the clinical curative effects and the proliferation of blast in acute leukemia.
  • Detection of LRP and GST activities in acute leukemia may have a reference value in judging the leukemia with drug resistance and estimating the prognosis.
  • [MeSH-major] Glutathione Transferase / metabolism. Leukemia, Myeloid, Acute / metabolism. Neoplasm Proteins / biosynthesis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Vault Ribonucleoprotein Particles / biosynthesis

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16045016.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


16. Wang HR, Gu CH, Zhu JY, Han JY, Zhong H, Chen FY, Ouyang RR: PNAS-2: a novel gene probably participating in leukemogenesis. Oncology; 2006;71(5-6):423-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: As(4)S(4) is an effective drug for the treatment of acute promyelocytic leukemia but its mechanism of action remains largely unknown.
  • METHODS: NB4 and U937 leukemia cell lines and serial clinical samples were studied.
  • PNAS-2 expression is significantly increased in de novo or relapsed acute leukemia, but in patients in complete remission PNAS-2 levels decrease to levels comparable to those found in normal controls.
  • In carcinomas, PNAS-2 expression was not upregulated, indicating that PNAS-2 overexpression was specific for leukemia.
  • [MeSH-major] Apoptosis / genetics. Apoptosis Regulatory Proteins / genetics. Cell Transformation, Neoplastic / genetics. Leukemia / genetics. Leukemia / metabolism

  • MedlinePlus Health Information. consumer health - Leukemia.
  • figshare. supplemental materials - Supporting Data and Materials for the article .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 S. Karger AG, Basel.
  • (PMID = 17855796.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / PNAS-2 protein, human; 0 / RNA, Small Interfering
  •  go-up   go-down


17. Bennett CL, Evens AM, Andritsos LA, Balasubramanian L, Mai M, Fisher MJ, Kuzel TM, Angelotta C, McKoy JM, Vose JM, Bierman PJ, Kuter DJ, Trifilio SM, Devine SM, Tallman MS: Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol; 2006 Dec;135(5):642-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) and granulocyte colony-stimulating factor (G-CSF) promote haematopoietic progenitor cell maturation.
  • We reviewed the findings for healthy volunteers/donors who developed haematological malignancies following PEG-rHuMGDF or G-CSF administration.
  • Information was reviewed for three of 538 volunteers who received PEG-rHuMGDF in clinical trials and two of 200 donors who underwent G-CSF mobilised stem cell harvesting procedures for sibling stem cell transplants.
  • Mantle cell, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia were diagnosed 1-5 years after PEG-rHuMGDF exposure among three volunteers.
  • Acute myeloid leukaemia was diagnosed 4 and 5 years after G-CSF mobilisation in two donors who underwent peripheral blood stem cell donation for sibling allogeneic haematopoietic stem cell transplantation.
  • Following intensive chemotherapy, one died from acute leukaemia and the second is in complete remission.
  • [MeSH-major] Hematologic Neoplasms / etiology. Hematopoietic Cell Growth Factors / adverse effects. Tissue Donors
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Autoantibodies / immunology. Clinical Trials as Topic. Female. Granulocyte Colony-Stimulating Factor / adverse effects. Humans. Leukemia, Erythroblastic, Acute / drug therapy. Leukemia, Erythroblastic, Acute / etiology. Leukemia, Erythroblastic, Acute / genetics. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / etiology. Leukemia, Monocytic, Acute / drug therapy. Leukemia, Monocytic, Acute / etiology. Leukemia, Monocytic, Acute / genetics. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / etiology. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Mantle-Cell / etiology. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Polyethylene Glycols / adverse effects. Recombinant Proteins / adverse effects. Thrombopoietin / adverse effects. Thrombopoietin / immunology

  • MedlinePlus Health Information. consumer health - Organ Donation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2007 Apr;137(1):77-8; author reply 79-80 [17359373.001]
  • [CommentIn] Br J Haematol. 2007 Apr;137(1):78-9; author reply 79-80 [17359374.001]
  • [CommentIn] Br J Haematol. 2006 Dec;135(5):651-2 [17054429.001]
  • (PMID = 17054431.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 1R01CA 102713-01; United States / NCI NIH HHS / CA / K23 CA109613-A1; United States / NCI NIH HHS / CA / P 30 CA60553
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Autoantibodies; 0 / Hematopoietic Cell Growth Factors; 0 / Recombinant Proteins; 0 / polyethylene glycol-recombinant human megakaryocyte growth and development factor; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 30IQX730WE / Polyethylene Glycols; 9014-42-0 / Thrombopoietin
  •  go-up   go-down


18. Ishmael J, Dugard PH: A review of perchloroethylene and rat mononuclear cell leukemia. Regul Toxicol Pharmacol; 2006 Jul;45(2):178-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A review of perchloroethylene and rat mononuclear cell leukemia.
  • Mononuclear cell leukemia (MNCL) is an extremely common spontaneous disease of ageing F344 rats accompanied by splenomegaly, anemia, thrombocytopenia, and leukemic infiltration (initially of the spleen, liver, and lung).
  • MNCL cells possess natural killer (NK) cell characteristics and apparently, the neoplastic cells derive from large granular lymphocytes (LGL), hence the alternative name of LGL leukemia.
  • LGL leukemia is uncommon in man and occurs in two forms: T-LGL leukemia which has a chronic course, and the much rarer NK-LGL leukemia.
  • In addition to cell type, the latter resembles F344 LGL leukemia being acute in course and involving more pronounced splenomegaly and thrombocytopenia.
  • Chemically related increases in MNCL in F344 rats have not been associated with induction of human LGL leukemia.
  • [MeSH-major] Carcinogens, Environmental / toxicity. Leukemia, Lymphoid / chemically induced. Tetrachloroethylene / toxicity

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • Hazardous Substances Data Bank. Tetrachloroethylene .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16684583.001).
  • [ISSN] 0273-2300
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinogens, Environmental; TJ904HH8SN / Tetrachloroethylene
  • [Number-of-references] 53
  •  go-up   go-down


19. Schmitt-Graeff A, Hochhaus A: [Hematological side effects of tyrosine kinase inhibition using imatinib]. Pathologe; 2006 Feb;27(1):40-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imatinib (STI571, Gleevec/Glivec) and other small-molecule tyrosine kinase inhibitors are highly effective in the treatment of chronic myeloid leukemia (CML), gastrointestinal stromal tumors and, for example, eosinophilia-associated chronic myeloproliferative disorders.
  • Loss of response to imatinib may be due to an acquired resistance of emerging mutant tumor cell clones.
  • However, toxicities including edema, skin rashes, fatigue, nausea and myelosuppression have been reported.
  • Single or multilineage myelodysplasia may be accompanied by an excess of blasts and rarely evolves into acute leukemia in CML patients.
  • [MeSH-minor] Benzamides. Gastrointestinal Diseases / chemically induced. Hematopoiesis / drug effects. Hematopoiesis / genetics. Humans. Imatinib Mesylate. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hematology Am Soc Hematol Educ Program. 2003;:132-52 [14633780.001]
  • [Cites] Curr Cancer Drug Targets. 2005 May;5(3):171-93 [15892618.001]
  • [Cites] Pharmacol Rev. 2003 Sep;55(3):401-23 [12869662.001]
  • [Cites] Blood. 2003 Mar 1;101(5):1941-9 [12411298.001]
  • [Cites] Acta Haematol. 2005;114(1):52-60 [15995325.001]
  • [Cites] Stem Cells. 2005 Sep;23(8):1082-8 [16140870.001]
  • [Cites] Leuk Lymphoma. 2005 May;46(5):781-4 [16019519.001]
  • [Cites] Leuk Lymphoma. 2004 Feb;45(2):237-45 [15101707.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Hematol Oncol Clin North Am. 2004 Jun;18(3):641-56, ix [15271397.001]
  • [Cites] Ann Hematol. 2005 Aug;84(8):487-97 [15931535.001]
  • [Cites] Blood. 2002 Jul 15;100(2):435-41 [12091333.001]
  • [Cites] Nature. 2005 Jun 30;435(7046):1267-70 [15988530.001]
  • [Cites] Expert Opin Drug Saf. 2005 Mar;4(2):183-91 [15794712.001]
  • [Cites] Leukemia. 2004 Aug;18(8):1340-6 [15190256.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):1781-8 [16136600.001]
  • [Cites] Pathologe. 2004 Nov;25(6):428-35 [15179523.001]
  • [Cites] Pathologe. 2004 Mar;25(2):127-34 [15010998.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Oct 1;129(40):2122-7 [15455305.001]
  • [Cites] Cancer. 2005 Apr 15;103(8):1659-69 [15747376.001]
  • [Cites] Blood. 2004 Jan 15;103(2):523-9 [12969987.001]
  • [Cites] Blood. 2002 May 15;99(10):3792-800 [11986238.001]
  • [Cites] Leukemia. 2005 Mar;19(3):460-3 [15625554.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:111-35 [12446421.001]
  • [Cites] Blood. 2002 Jan 1;99(1):381-3 [11756197.001]
  • [Cites] Cell Cycle. 2005 Jul;4(7):851-3 [15917650.001]
  • [Cites] N Engl J Med. 2003 Mar 13;348(11):994-1004 [12637609.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1573-8 [15990860.001]
  • [Cites] Eur J Cancer. 2005 Aug;41(12):1751-7 [16098458.001]
  • [Cites] Ann N Y Acad Sci. 2005 Jun;1044:168-77 [15958710.001]
  • [Cites] Blood. 2004 Oct 1;104(7):1931-9 [15166033.001]
  • [Cites] Histol Histopathol. 2004 Oct;19(4):1277-88 [15375771.001]
  • [Cites] Blood. 2002 May 15;99(10):3530-9 [11986204.001]
  • [Cites] Leuk Res. 2003 Dec;27(12):1163-6 [12921956.001]
  • [Cites] Bone Marrow Transplant. 2005 Sep;36(5):417-24 [16007105.001]
  • (PMID = 16421705.001).
  • [ISSN] 0172-8113
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


20. Bernard N, Devevey L, Jacquemont C, Chrétien P, Helissey P, Guillosson JJ, Arock M, Nafziger J: A new model of pre-B acute lymphoblastic leukemia chemically induced in rats. Exp Hematol; 2005 Oct;33(10):1130-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A new model of pre-B acute lymphoblastic leukemia chemically induced in rats.
  • OBJECTIVE: Although B acute lymphoblastic leukemia (B-ALL) is the most common leukemia among children, no chemically inducible model of this leukemia has yet been described in vivo.
  • METHODS: Leukemia was chemically induced in male WKAH/Hkm rats by a nitrosourea derivative, N-butylnitrosourea (BNU), an alkylating agent, administered orally 5 days a week for 24 weeks.
  • Development of leukemia was monitored by clinical observation, follow-up of blood parameters, and appearance of blast cells in peripheral blood samples.
  • The phenotype of the leukemia was determined by cytological examination, cytochemical reactions, and by immunophenotyping of bone marrow cells using various markers.
  • The feasibility of leukemia transplantation was investigated.
  • RESULTS: We observed the appearance of acute leukemia in 60% of the rats treated with BNU.
  • CONCLUSION: This new in vivo model of inducible pre-B-ALL might be useful for investigating the effects of co-initiating or promoting agents suspected to be involved in leukemia development, and for disclosing new molecular events leading to leukemogenic processes.
  • [MeSH-major] Carcinogens / toxicity. Leukemia, Experimental / pathology. Nitrosourea Compounds / toxicity. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Hazardous Substances Data Bank. N-NITROSO-N-BUTYLUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16219535.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Carcinogens; 0 / Nitrosourea Compounds; 869-01-2 / N-nitrosobutylurea
  •  go-up   go-down


21. Dagbashian SS: [Characteristics of respiratory disorders in acute leukemia]. Ter Arkh; 2007;79(12):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Characteristics of respiratory disorders in acute leukemia].
  • AIM: To characterize respiratory disorders and microflora in patients with acute leukemia (AL).
  • Blast pleurisy was found in 6 patients.
  • [MeSH-major] Leukemia / complications. Respiratory Tract Infections / complications
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Anti-Bacterial Agents / therapeutic use. Bacteria / isolation & purification. Diagnosis, Differential. Follow-Up Studies. Humans. Middle Aged. Prognosis. Radiography, Thoracic. Retrospective Studies. Sputum / microbiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18220035.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


22. Tajeddine N, Gala JL, Louis M, Van Schoor M, Tombal B, Gailly P: Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo. Cancer Res; 2005 Aug 15;65(16):7348-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor-associated antigen preferentially expressed antigen of melanoma (PRAME) induces caspase-independent cell death in vitro and reduces tumorigenicity in vivo.
  • Preferentially expressed antigen of melanoma (PRAME) is expressed in a wide variety of tumors, but in contrast with most other tumor associated antigens, it is also expressed in leukemias.
  • Interestingly, PRAME expression is correlated with a favorable prognosis in childhood acute leukemias.
  • Moreover, a high expression of PRAME seems to be predominantly found in acute leukemias carrying a favorable prognosis.
  • On these clinical observations, we assumed that PRAME could be involved in the regulation of cell death or cell cycle.
  • In this study, we show that transient overexpression of PRAME induces a caspase-independent cell death in cultured cell lines (CHO-K1 and HeLa).
  • Cells stably transfected with PRAME also exhibit a decreased proliferation rate due, at least partially, to an elevated basal rate of cell death.
  • Immunocytochemistry of a FLAG-tagged PRAME, in vivo imaging of an enhanced green fluorescent protein-tagged PRAME, and Western blotting after cell fractionation reveal a nuclear localization of the protein.
  • We suggest that all these observations might explain the favorable prognosis of the leukemias expressing high levels of PRAME.
  • [MeSH-minor] Animals. CHO Cells. Caspases / metabolism. Cell Cycle Proteins / biosynthesis. Cell Cycle Proteins / genetics. Cell Growth Processes / physiology. Cell Nucleus / metabolism. Cricetinae. Cyclin-Dependent Kinase Inhibitor p21. Down-Regulation. HSP27 Heat-Shock Proteins. HeLa Cells. Heat-Shock Proteins / biosynthesis. Heat-Shock Proteins / genetics. Humans. K562 Cells. Mice. Mice, Nude. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. S100 Proteins / biosynthesis. S100 Proteins / genetics. Transfection

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16103086.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / CDKN1A protein, human; 0 / Cdkn1a protein, mouse; 0 / Cell Cycle Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / HSP27 Heat-Shock Proteins; 0 / HSPB1 protein, human; 0 / Heat-Shock Proteins; 0 / Neoplasm Proteins; 0 / PRAME protein, human; 0 / Recombinant Fusion Proteins; 0 / S100 Proteins; 0 / S100a4 protein, mouse; 142662-27-9 / S100A4 protein, human; EC 3.4.22.- / Caspases
  •  go-up   go-down


23. Wiederschain D, Kawai H, Shilatifard A, Yuan ZM: Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage. J Biol Chem; 2005 Jul 1;280(26):24315-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple mixed lineage leukemia (MLL) fusion proteins suppress p53-mediated response to DNA damage.
  • Chromosomal translocations involving the mixed lineage leukemia (MLL) gene are often observed in acute leukemias of both myeloid and lymphocytic origin.
  • [MeSH-minor] Blotting, Western. Cell Line, Tumor. DNA Primers / chemistry. Humans. Immunoprecipitation. Luciferases / metabolism. Models, Genetic. Myeloid-Lymphoid Leukemia Protein. Plasmids / metabolism. Protein Structure, Tertiary. RNA / chemistry. Radiation, Ionizing. Recombinant Fusion Proteins / chemistry. Retroviridae / genetics. Reverse Transcriptase Polymerase Chain Reaction. Transcription, Genetic. Transcriptional Activation. Transfection. Translocation, Genetic

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15851483.001).
  • [ISSN] 0021-9258
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] eng
  • [Grant] United States / NIEHS NIH HHS / ES / ES11627; United States / NCI NIH HHS / CA / R01 CA85679-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA Primers; 0 / MLL-AF10 fusion protein, human; 0 / MLL-AF9 fusion protein, human; 0 / MLL-ELL fusion protein, human; 0 / MLL-ENL oncoprotein, human; 0 / Oncogene Proteins, Fusion; 0 / Recombinant Fusion Proteins; 0 / Tumor Suppressor Protein p53; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 63231-63-0 / RNA; EC 1.13.12.- / Luciferases
  •  go-up   go-down


24. Janes MR, Limon JJ, So L, Chen J, Lim RJ, Chavez MA, Vu C, Lilly MB, Mallya S, Ong ST, Konopleva M, Martin MB, Ren P, Liu Y, Rommel C, Fruman DA: Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med; 2010 Feb;16(2):205-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.
  • We compared rapamycin with PP242, an inhibitor of the active site of mTOR in both TORC1 and TORC2 (hereafter referred to as TORC1/2), in models of acute leukemia harboring the Philadelphia chromosome (Ph) translocation.
  • We demonstrate that PP242, but not rapamycin, causes death of mouse and human leukemia cells.
  • In vivo, PP242 delays leukemia onset and augments the effects of the current front-line tyrosine kinase inhibitors more effectively than does rapamycin.
  • These findings establish that Ph(+) transformed cells are more sensitive than normal lymphocytes to selective TORC1/2 inhibitors and support the development of such inhibitors for leukemia therapy.


25. Cheadle EJ: MT-103 Micromet/MedImmune. Curr Opin Mol Ther; 2006 Feb;8(1):62-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Micromet AG and Medlmmune Inc are developing MT-103, a single-chain bispecific recombinant antibody from Micromet's BiTE (bispecific T-cell engager) product platform that binds both the CD19 antigen and the T-cell receptor (CD3), for the potential treatment of B-cell lymphoma.
  • The company is also investigating the compound for the potential treatment of chronic lymphocytic leukemia and acute lymphoblastic leukemia.
  • [MeSH-minor] Animals. Clinical Trials, Phase I as Topic. Humans. Lymphoma, B-Cell / drug therapy. Structure-Activity Relationship

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16506527.001).
  • [ISSN] 1464-8431
  • [Journal-full-title] Current opinion in molecular therapeutics
  • [ISO-abbreviation] Curr. Opin. Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Bispecific; 4FR53SIF3A / blinatumomab
  •  go-up   go-down


26. Mejstrikova E, Volejnikova J, Fronkova E, Zdrahalova K, Kalina T, Sterba J, Jabali Y, Mihal V, Blazek B, Cerna Z, Prochazkova D, Hak J, Zemanova Z, Jarosova M, Oltova A, Sedlacek P, Schwarz J, Zuna J, Trka J, Stary J, Hrusak O: Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. Haematologica; 2010 Jun;95(6):928-35
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria.
  • BACKGROUND: Mixed phenotype acute leukemia (MPAL) represents a diagnostic and therapeutic dilemma.
  • The European Group for the Immunological Classification of Leukemias (EGIL) scoring system unambiguously defines MPAL expressing aberrant lineage markers.
  • DESIGN AND METHODS: Simple immunophenotypic criteria were used to classify all cases of childhood acute leukemia in order to provide therapy directed against acute lymphoblastic leukemia or acute myeloid leukemia.
  • Prognosis, genotype and immunoglobulin/T-cell receptor gene rearrangement status were analyzed.
  • RESULTS: The incidences of MPAL were 28/582 and 4/107 for children treated with acute lymphoblastic leukemia and acute myeloid leukemia regimens, respectively.
  • In immunophenotypic principal component analysis, MPAL treated as T-cell acute lymphoblastic leukemia clustered between cases of non-mixed T-cell acute lymphoblastic leukemia and acute myeloid leukemia, while other MPAL cases were included in the respective non-mixed B-cell progenitor acute lymphoblastic leukemia or acute myeloid leukemia clusters.
  • Analogously, immunoglobulin/T-cell receptor gene rearrangements followed the expected pattern in patients treated as having acute myeloid leukemia (non-rearranged, 4/4) or as having B-cell progenitor acute lymphoblastic leukemia (rearranged, 20/20), but were missing in 3/5 analyzed cases of MPAL treated as having T-cell acute lymphobastic leukemia.
  • In patients who received acute lymphoblastic leukemia treatment, the 5-year event-free survival of the MPAL cases was worse than that of the non-mixed cases (53+/-10% and 76+/-2% at 5 years, respectively, P=0.0075), with a more pronounced difference among B lineage cases.
  • The small numbers of MPAL cases treated as T-cell acute lymphoblastic leukemia or as acute myeloid leukemia hampered separate statistics.
  • In B lineage leukemia, MPAL confers poorer prognosis.
  • However, our data do not justify a preferential use of current acute myeloid leukemia-based therapy in MPAL.
  • [MeSH-major] Immunophenotyping. Leukemia / diagnosis. Leukemia / therapy. Phenotype
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Follow-Up Studies. Humans. Infant. Infant, Newborn. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Leukemia, Myeloid, Acute / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis. Receptors, Antigen, T-Cell / immunology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2005 Jun;19(6):1092-4 [15830012.001]
  • [Cites] J Immunol. 2005 Aug 15;175(4):2495-500 [16081821.001]
  • [Cites] Blood. 2005 Dec 15;106(13):4414-5 [16326981.001]
  • [Cites] Leukemia. 2006 Mar;20(3):410-6 [16424874.001]
  • [Cites] Leukemia. 2006 Apr;20(4):620-6 [16437134.001]
  • [Cites] Blood. 2006 Jun 1;107(11):4508-13 [16493009.001]
  • [Cites] Curr Opin Pediatr. 2007 Feb;19(1):1-8 [17224655.001]
  • [Cites] Leukemia. 2007 Nov;21(11):2264-70 [17611554.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):977-83 [18281529.001]
  • [Cites] Blood. 2009 May 21;113(21):5083-9 [19131545.001]
  • [Cites] Haematologica. 2009 Jul;94(7):919-27 [19454497.001]
  • [Cites] Am J Clin Pathol. 2009 Aug;132(2):182-5; quiz 306 [19605811.001]
  • [Cites] Pediatr Blood Cancer. 2010 Jan;54(1):62-70 [19760767.001]
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):59-75 [10986407.001]
  • [Cites] Br J Haematol. 2001 Jun;113(3):757-62 [11380467.001]
  • [Cites] Leukemia. 2002 Mar;16(3):368-75 [11896540.001]
  • [Cites] Leukemia. 2002 Jul;16(7):1233-58 [12094248.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):95-6 [12764763.001]
  • [Cites] Nat Immunol. 2003 Jun;4(6):533-9 [12717433.001]
  • [Cites] J Immunol. 2003 Jul 15;171(2):524-7 [12847212.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2149-56 [14576730.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Aug;153(1):88-9 [15325104.001]
  • [Cites] Haematologica. 1991 May-Jun;76(3):215-25 [1743592.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] Am J Hematol. 1996 Feb;51(2):147-51 [8579056.001]
  • [Cites] Haematologica. 1997 Jan-Feb;82(1):64-6 [9107085.001]
  • [Cites] Br J Haematol. 1997 Oct;99(1):101-6 [9359509.001]
  • [Cites] Blood. 1998 Jul 15;92(2):596-9 [9657760.001]
  • [Cites] Leukemia. 1999 Feb;13(2):196-205 [10025893.001]
  • [Cites] Haematologica. 1999 Aug;84(8):699-706 [10457405.001]
  • [Cites] Leuk Res. 2005 Jun;29(6):633-9 [15863202.001]
  • [Cites] BMC Cancer. 2005;5:38 [15826304.001]
  • (PMID = 20145275.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Receptors, Antigen, T-Cell
  • [Other-IDs] NLM/ PMC2878790
  •  go-up   go-down


27. Reitman ZJ, Yan H: Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst; 2010 Jul 7;102(13):932-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We review the normal functions of the encoded enzymes, frequent mutations of IDH1 and IDH2 recently found in human cancers, and possible roles for the mutated enzymes in human disease.
  • IDH1 and IDH2 mutations occur frequently in some types of World Health Organization grades 2-4 gliomas and in acute myeloid leukemias with normal karyotype.

  • Genetics Home Reference. consumer health - IDH1 gene.
  • Genetics Home Reference. consumer health - IDH2 gene.
  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2006 Nov 24;281(47):35624-32 [17001083.001]
  • [Cites] J Biol Chem. 2007 May 4;282(18):13385-94 [17350954.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Mol Cell Biochem. 2007 Aug;302(1-2):27-34 [17646934.001]
  • [Cites] PLoS One. 2007;2(8):e690 [17668068.001]
  • [Cites] Free Radic Biol Med. 2007 Oct 15;43(8):1197-207 [17854715.001]
  • [Cites] J Inherit Metab Dis. 2007 Oct;30(5):690-3 [17876720.001]
  • [Cites] Annu Rev Pathol. 2006;1:97-117 [18039109.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Feb 22;366(4):1012-8 [18096511.001]
  • [Cites] Free Radic Res. 2008 May;42(5):467-73 [18484410.001]
  • [Cites] Neuroscience. 2008 Jun 26;154(3):1107-20 [18495355.001]
  • [Cites] Free Radic Res. 2008 Jul;42(7):618-24 [18608518.001]
  • [Cites] Biochimie. 2008 Sep;90(9):1316-24 [18405671.001]
  • [Cites] Neuropediatrics. 2008 Apr;39(2):119-22 [18671189.001]
  • [Cites] Nat Genet. 2008 Oct;40(10):1230-4 [18806796.001]
  • [Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):597-602 [18985363.001]
  • [Cites] Hum Mutat. 2009 Jan;30(1):7-11 [19117336.001]
  • [Cites] Free Radic Res. 2009 Feb;43(2):165-73 [19204869.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):765-73 [19228619.001]
  • [Cites] N Engl J Med. 2009 Feb 19;360(8):813-5 [19228626.001]
  • [Cites] Free Radic Res. 2009 Apr;43(4):409-16 [19291592.001]
  • [Cites] Am J Pathol. 2009 Apr;174(4):1149-53 [19246647.001]
  • [Cites] Science. 2009 Apr 10;324(5924):261-5 [19359588.001]
  • [Cites] Acta Neuropathol. 2009 Jun;117(6):653-6 [19340432.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2248; author reply 2249 [19458374.001]
  • [Cites] N Engl J Med. 2009 May 21;360(21):2248-9; author reply 2249 [19469031.001]
  • [Cites] Int J Cancer. 2009 Jul 15;125(2):353-5 [19378339.001]
  • [Cites] Acta Neuropathol. 2009 Sep;118(3):401-5 [19543740.001]
  • [Cites] Neuro Oncol. 2009 Aug;11(4):341-7 [19435942.001]
  • [Cites] J Clin Oncol. 2009 Sep 1;27(25):4150-4 [19636000.001]
  • [Cites] Acta Neuropathol. 2009 Oct;118(4):469-74 [19554337.001]
  • [Cites] N Engl J Med. 2009 Sep 10;361(11):1058-66 [19657110.001]
  • [Cites] Int J Cancer. 2009 Nov 15;125(10):2485-6 [19530255.001]
  • [Cites] Clin Cancer Res. 2009 Oct 1;15(19):6002-7 [19755387.001]
  • [Cites] Nature. 2009 Dec 10;462(7274):739-44 [19935646.001]
  • [Cites] N Engl J Med. 2010 Jan 28;362(4):369-70 [20107228.001]
  • [Cites] Cancer Cell. 2010 Jan 19;17(1):7-9 [20129244.001]
  • [Cites] J Exp Med. 2010 Feb 15;207(2):339-44 [20142433.001]
  • [Cites] Cancer Sci. 2009 Dec;100(12):2235-41 [19737147.001]
  • [Cites] Hum Mutat. 2010 Mar;31(3):279-83 [20020533.001]
  • [Cites] Cancer Cell. 2010 Mar 16;17(3):225-34 [20171147.001]
  • [Cites] Acta Neuropathol. 2010 Apr;119(4):487-94 [20127344.001]
  • [Cites] J Biol Chem. 2000 Feb 25;275(8):5606-12 [10681542.001]
  • [Cites] J Histochem Cytochem. 2001 Sep;49(9):1123-31 [11511681.001]
  • [Cites] Biochimie. 2001 Nov-Dec;83(11-12):1057-65 [11879734.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Mar 29;292(2):542-9 [11906195.001]
  • [Cites] Free Radic Biol Med. 2002 Jun 1;32(11):1185-96 [12031902.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2002 Oct;283(4):H1505-14 [12234803.001]
  • [Cites] Free Radic Biol Med. 2002 Oct 1;33(7):927-37 [12361803.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):43454-62 [12207025.001]
  • [Cites] J Lipid Res. 2003 Nov;44(11):2169-80 [12923220.001]
  • [Cites] J Biol Chem. 2003 Dec 19;278(51):51360-71 [14551203.001]
  • [Cites] Free Radic Res. 2004 Mar;38(3):241-9 [15129732.001]
  • [Cites] J Comput Chem. 2004 Oct;25(13):1605-12 [15264254.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33946-57 [15173171.001]
  • [Cites] J Biol Chem. 2004 Sep 17;279(38):39968-74 [15254034.001]
  • [Cites] Biochimie. 2004 Aug;86(8):501-7 [15388226.001]
  • [Cites] Metabolism. 1986 Jul;35(7):661-7 [3724458.001]
  • [Cites] Exp Eye Res. 1986 Nov;43(5):829-47 [3803464.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Nov;86(22):8635-9 [2682654.001]
  • [Cites] J Biol Chem. 1989 Dec 5;264(34):20482-6 [2511204.001]
  • [Cites] J Biol Chem. 1990 Mar 5;265(7):3599-602 [2406256.001]
  • [Cites] Science. 1990 Aug 31;249(4972):1012-6 [2204109.001]
  • [Cites] Science. 1990 Aug 31;249(4972):1044-6 [2204110.001]
  • [Cites] J Biol Chem. 1993 Jun 5;268(16):12116-22 [8099357.001]
  • [Cites] Biochemistry. 1993 Sep 14;32(36):9302-9 [8369299.001]
  • [Cites] FEBS Lett. 1994 May 16;344(2-3):109-16 [8187868.001]
  • [Cites] J Biol Chem. 1994 Sep 16;269(37):23128-34 [8083215.001]
  • [Cites] J Cell Biochem. 1996 Mar 15;60(4):495-507 [8707889.001]
  • [Cites] Biochemistry. 1997 Nov 4;36(44):13743-7 [9354646.001]
  • [Cites] EMBO J. 1998 Feb 2;17(3):677-87 [9450993.001]
  • [Cites] J Biol Chem. 1998 Feb 6;273(6):3702-11 [9452501.001]
  • [Cites] Mol Biol Evol. 1998 Dec;15(12):1674-84 [9866202.001]
  • [Cites] J Biol Chem. 1999 Feb 5;274(6):3402-6 [9920883.001]
  • [Cites] J Biol Chem. 1999 Oct 22;274(43):30527-33 [10521434.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Dec 3;325(1):32-8 [15522197.001]
  • [Cites] Free Radic Biol Med. 2004 Dec 1;37(11):1765-78 [15528036.001]
  • [Cites] Int J Radiat Biol. 2004 Sep;80(9):635-42 [15586883.001]
  • [Cites] Redox Rep. 2004;9(5):271-7 [15606980.001]
  • [Cites] Antioxid Redox Signal. 2005 May-Jun;7(5-6):823-8 [15890030.001]
  • [Cites] Oncogene. 2006 Aug 7;25(34):4675-82 [16892081.001]
  • [Cites] J Biol Chem. 2006 Oct 13;281(41):30593-602 [16912049.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • (PMID = 20513808.001).
  • [ISSN] 1460-2105
  • [Journal-full-title] Journal of the National Cancer Institute
  • [ISO-abbreviation] J. Natl. Cancer Inst.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA140316; United States / NIGMS NIH HHS / GM / 2T32GM007171; United States / NCI NIH HHS / CA / R01CA118822
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / Glutarates; 2889-31-8 / alpha-hydroxyglutarate; 53-59-8 / NADP; 94ZLA3W45F / Arginine; EC 1.1.1.41 / Isocitrate Dehydrogenase; EC 1.1.1.41 / isocitrate dehydrogenase 2, human; EC 1.1.1.42. / IDH1 protein, human; IY9XDZ35W2 / Glucose
  • [Number-of-references] 86
  • [Other-IDs] NLM/ PMC2897878
  •  go-up   go-down


28. Palomero T, McKenna K, O-Neil J, Galinsky I, Stone R, Suzukawa K, Stiakaki E, Kalmanti M, Fox EA, Caligiuri MA, Aster JC, Look AT, Ferrando AA: Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia; 2006 Nov;20(11):1963-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias.
  • Activating mutations in NOTCH1 are found in over 50% of human T-cell lymphoblastic leukemias (T-ALLs).
  • Here, we report the analysis for activating NOTCH1 mutations in a large number of acute myeloid leukemia (AML) primary samples and cell lines.
  • We found activating mutations in NOTCH1 in a single M0 primary AML sample, in three (ML1, ML2 and CTV-1) out of 23 AML cell lines and in the diagnostic (myeloid) and relapsed (T-lymphoid) clones in a patient with lineage switch leukemia.
  • Importantly, the ML1 and ML2 AML cell lines are derived from an AML relapse in a patient initially diagnosed with T-ALL.
  • The presence of NOTCH1 mutations in myeloid and T-lymphoid clones in lineage switch leukemias establishes the common clonal origin of the diagnostic and relapse blast populations and suggests a stem cell origin of NOTCH1 mutations during the molecular pathogenesis of these tumors.
  • [MeSH-major] Cell Lineage / genetics. Gene Expression Regulation, Leukemic. Leukemia, Myeloid / genetics. Leukemia, Myeloid / pathology. Receptor, Notch1 / genetics
  • [MeSH-minor] Acute Disease. Base Sequence. Cell Line, Tumor. Gene Deletion. Hematopoietic Stem Cells / pathology. Hematopoietic Stem Cells / physiology. Humans. Point Mutation. Recurrence. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008890.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA109901; United States / NCI NIH HHS / CA / CA68484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / NOTCH1 protein, human; 0 / Receptor, Notch1
  •  go-up   go-down


29. Belson M, Kingsley B, Holmes A: Risk factors for acute leukemia in children: a review. Environ Health Perspect; 2007 Jan;115(1):138-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for acute leukemia in children: a review.
  • Although overall incidence is rare, leukemia is the most common type of childhood cancer.
  • Within this population, acute lymphocytic leukemia (ALL) occurs approximately five times more frequently than acute myelogenous leukemia (AML) and accounts for approximately 78% of all childhood leukemia diagnoses.
  • Epidemiologic studies of acute leukemias in children have examined possible risk factors, including genetic, infectious, and environmental, in an attempt to determine etiology.
  • Most environmental risk factors have been found to be weakly and inconsistently associated with either form of acute childhood leukemia.
  • Our review focuses on the demographics of childhood leukemia and the risk factors that have been associated with the development of childhood ALL or AML.
  • The environmental risk factors discussed include ionizing radiation, non-ionizing radiation, hydrocarbons, pesticides, alcohol use, cigarette smoking, and illicit drug use.
  • Knowledge of these particular risk factors can be used to support measures to reduce potentially harmful exposures and decrease the risk of disease.
  • We also review genetic and infectious risk factors and other variables, including maternal reproductive history and birth characteristics.
  • [MeSH-major] Leukemia, Myeloid, Acute / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology
  • [MeSH-minor] Child. Communicable Diseases / complications. Environmental Exposure. Genetic Predisposition to Disease. Humans. Risk Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1989 Jul 15;49(14):4030-7 [2736544.001]
  • [Cites] BMJ. 1990 Feb 17;300(6722):423-9 [2107892.001]
  • [Cites] Am J Hum Genet. 1990 Jun;46(6):1041-52 [2160192.001]
  • [Cites] Pediatr Hematol Oncol. 1987;4(1):63-72 [3152913.001]
  • [Cites] Br J Cancer. 1990 Dec;62(6):1008-14 [2257204.001]
  • [Cites] Environ Health Perspect. 1990 Aug;88:325-37 [2272330.001]
  • [Cites] Med J Aust. 1991 Apr 1;154(7):483-7 [2005848.001]
  • [Cites] BMJ. 1991 Mar 23;302(6778):681-7 [2021741.001]
  • [Cites] BMJ. 1991 Mar 23;302(6778):687-92 [2021742.001]
  • [Cites] Cancer. 1991 Sep 15;68(6):1351-5 [1873786.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):549-54 [1911197.001]
  • [Cites] Br J Cancer. 2001 Feb 2;84(3):406-12 [11161408.001]
  • [Cites] Int J Epidemiol. 2001 Feb;30(1):125-9 [11171872.001]
  • [Cites] Am J Epidemiol. 2001 Mar 15;153(6):615-7 [11257071.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2542-6 [11289128.001]
  • [Cites] Am J Public Health. 2001 Apr;91(4):564-7 [11291366.001]
  • [Cites] Cancer Causes Control. 2001 Aug;12(6):483-90 [11519756.001]
  • [Cites] Paediatr Perinat Epidemiol. 2001 Oct;15(4):338-45 [11703681.001]
  • [Cites] Radiat Res. 2001 Dec;156(6):718-23 [11741495.001]
  • [Cites] Environ Health Perspect. 1991 Aug;94:5-7 [1954939.001]
  • [Cites] Eur J Cancer. 1992;29A(1):87-95 [1445751.001]
  • [Cites] BMJ. 1993 Jan 9;306(6870):89-94 [8435648.001]
  • [Cites] Leukemia. 1993 Mar;7(3):349-60 [8445941.001]
  • [Cites] BMJ. 1993 Mar 6;306(6878):615-21 [8461811.001]
  • [Cites] BMJ. 1993 May 1;306(6886):1153-8 [8499814.001]
  • [Cites] Leukemia. 1993 Aug;7 Suppl 2:S146-7 [8361221.001]
  • [Cites] BMJ. 1993 Oct 16;307(6910):959-66 [8241906.001]
  • [Cites] Med Pediatr Oncol. 1994;22(2):78-83 [8259105.001]
  • [Cites] Nature. 1994 Feb 24;367(6465):678-80 [8107860.001]
  • [Cites] BMJ. 1994 Jul 16;309(6948):154-7 [8044093.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Sep;3(6):457-60 [8000294.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):1-5 [7819022.001]
  • [Cites] Am J Public Health. 1995 Feb;85(2):249-52 [7856787.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Dec;3(8):645-53 [7881337.001]
  • [Cites] Cancer. 1995 Apr 15;75(8):2186-95 [7697611.001]
  • [Cites] Epidemiol Rev. 1994;16(2):243-72 [7713179.001]
  • [Cites] Environ Health Perspect. 1995 Jun;103(6):550-4 [7556005.001]
  • [Cites] Eur J Cancer Prev. 1995 Sep;4 Suppl 1:3-107 [7496333.001]
  • [Cites] J Natl Cancer Inst. 1996 Jan 3;88(1):24-31 [8847721.001]
  • [Cites] Ann Epidemiol. 1995 Sep;5(5):354-9 [8653207.001]
  • [Cites] Environ Health Perspect. 1995 Sep;103 Suppl 6:177-84 [8549470.001]
  • [Cites] Epidemiology. 1999 Sep;10(5):481-7 [10468419.001]
  • [Cites] JAMA. 2003 Oct 15;290(15):2001-7 [14559953.001]
  • [Cites] Curr Opin Pediatr. 2004 Feb;16(1):9-14 [14758108.001]
  • [Cites] Environ Mol Mutagen. 2004;43(2):100-9 [14991750.001]
  • [Cites] Cancer Detect Prev. 2004;28(2):83-7 [15068830.001]
  • [Cites] Cancer Res. 1967 Dec;27(12):2420-3 [4230121.001]
  • [Cites] J Natl Cancer Inst. 1968 May;40(5):1079-85 [5648133.001]
  • [Cites] Nature. 1971 Apr 9;230(5293):370-3 [4927726.001]
  • [Cites] Lancet. 1971 Apr 3;1(7701):699-701 [4101637.001]
  • [Cites] Science. 1973 Dec 28;182(4119):1355-6 [4586464.001]
  • [Cites] J Med Genet. 1977 Apr;14(2):81-90 [856959.001]
  • [Cites] Cancer Res. 1978 Mar;38(3):485-93 [203382.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1675-8 [6929216.001]
  • [Cites] J Pediatr. 1981 Sep;99(3):425-8 [7264801.001]
  • [Cites] Am J Ind Med. 1981;2(3):217-45 [7345926.001]
  • [Cites] J Occup Med. 1984 Sep;26(9):679-82 [6207280.001]
  • [Cites] Leuk Res. 1985;9(6):817-23 [3159943.001]
  • [Cites] Am J Epidemiol. 1985 Feb;121(2):216-24 [3860001.001]
  • [Cites] Nature. 1987 Jan 22-28;325(6102):355-7 [3808031.001]
  • [Cites] Br J Cancer. 1987 Feb;55(2):179-90 [3814487.001]
  • [Cites] J Natl Cancer Inst. 1987 Jul;79(1):39-46 [3474448.001]
  • [Cites] Prog Clin Biol Res. 1987;246:19-32 [2958880.001]
  • [Cites] Am J Epidemiol. 1988 Apr;127(4):713-25 [3354538.001]
  • [Cites] Int J Epidemiol. 2001 Dec;30(6):1428-37 [11821358.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • [Cites] Lancet. 2002 Feb 2;359(9304):431-4 [11844534.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Feb;11(2):177-85 [11867505.001]
  • [Cites] Environ Health Perspect. 2002 Mar;110(3):319-24 [11882484.001]
  • [Cites] Rev Environ Health. 2001 Jul-Sep;16(4):263-79 [12041882.001]
  • [Cites] Lancet Oncol. 2002 May;3(5):269-79 [12067803.001]
  • [Cites] Environ Health Perspect. 2002 Sep;110(9):955-60 [12204832.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):740-5 [12232757.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15101-6 [12415113.001]
  • [Cites] Pharmacogenetics. 2002 Nov;12(8):655-8 [12439226.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 9;94(25):13950-4 [9391133.001]
  • [Cites] Br J Cancer. 1998 Mar;77(5):842-9 [9514068.001]
  • [Cites] Epidemiology. 1998 May;9(3):234-45 [9583414.001]
  • [Cites] Leukemia. 1998 May;12(5):645-51 [9593260.001]
  • [Cites] Environ Health Perspect. 1998 Jun;106 Suppl 3:893-908 [9646054.001]
  • [Cites] Br J Cancer. 1998 Jul;78(1):119-24 [9662261.001]
  • [Cites] Radiat Environ Biophys. 1998 Jul;37(2):87-93 [9728740.001]
  • [Cites] Radiat Res. 1998 Nov;150(5 Suppl):S30-41 [9806607.001]
  • [Cites] Cancer. 1999 Mar 15;85(6):1380-8 [10189146.001]
  • [Cites] Teratology. 1999 Apr;59(4):227-33 [10331524.001]
  • [Cites] J Natl Cancer Inst. 1999 Jun 16;91(12):1051-8 [10379968.001]
  • [Cites] Int J Radiat Biol. 1999 Jul;75(7):801-10 [10489891.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):783-91 [10498397.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Sep;8(9):793-9 [10498398.001]
  • [Cites] Br J Cancer. 1999 Oct;81(3):549-53 [10507784.001]
  • [Cites] N Engl J Med. 1955 Jul 21;253(3):88-90 [14394332.001]
  • [Cites] Lancet. 1956 Sep 1;271(6940):447 [13358242.001]
  • [Cites] Arch Intern Med. 1961 Jul;108:86-90 [13720079.001]
  • [Cites] N Engl J Med. 1965 Apr 29;272:882-7 [14274439.001]
  • [Cites] N Engl J Med. 1959 Sep 17;261:585-9 [14425443.001]
  • [Cites] J Epidemiol Community Health. 2005 Feb;59(2):101-5 [15650139.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):651-5 [15767345.001]
  • [Cites] Environ Health. 2004;3(1):12 [15533260.001]
  • [Cites] Occup Environ Med. 2006 Feb;63(2):131-4 [16421392.001]
  • [Cites] Environ Health Perspect. 2003 Apr;111(4):663-8 [12676632.001]
  • [Cites] Hematol Oncol. 2003 Jun;21(2):51-5 [12802809.001]
  • [Cites] Environ Health Perspect. 2003 Jun;111(7):962-70 [12782499.001]
  • [Cites] Epidemiology. 2003 Jul;14(4):437-41 [12843769.001]
  • [Cites] Epidemiology. 2003 Sep;14(5):569-77 [14501272.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2321-33 [12791663.001]
  • [Cites] Lancet. 1988 Sep 17;2(8612):665-9 [2901525.001]
  • [Cites] Lancet. 1988 Dec 10;2(8624):1323-7 [2904050.001]
  • [Cites] Cancer. 1989 May 15;63(10):1904-11 [2649219.001]
  • [Cites] Radiat Res. 1996 May;145(5):595-601 [8619025.001]
  • [Cites] Br J Cancer. 1996 Apr;73(8):1006-12 [8611419.001]
  • [Cites] Med Pediatr Oncol Suppl. 1996;1:29-34 [8643045.001]
  • [Cites] Nature. 1996 Jul 25;382(6589):352-3 [8684463.001]
  • [Cites] Int J Cancer. 1996 Jul 29;67(3):343-52 [8707407.001]
  • [Cites] Cancer. 1995 Apr 1;75(7):1718-27 [8826933.001]
  • [Cites] Cancer Causes Control. 1996 Nov;7(6):581-90 [8932918.001]
  • [Cites] J Natl Cancer Inst. 1997 Feb 5;89(3):238-44 [9017004.001]
  • [Cites] Br J Cancer. 1997;75(3):457-63 [9020498.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1):3-16 [9045302.001]
  • [Cites] Occup Environ Med. 1996 Nov;53(11):773-81 [9038803.001]
  • [Cites] Br J Radiol. 1997 Feb;70:130-9 [9135438.001]
  • [Cites] Ann Epidemiol. 1997 Apr;7(3):172-9 [9141639.001]
  • [Cites] Cancer. 1997 May 15;79(10):2045-51 [9149034.001]
  • [Cites] Nature. 1997 May 15;387(6630):246 [9153387.001]
  • [Cites] Occup Environ Med. 1997 Mar;54(3):152-66 [9155776.001]
  • [Cites] N Engl J Med. 1997 Jul 3;337(1):1-7 [9203424.001]
  • [Cites] J Natl Cancer Inst. 1997 Jul 2;89(13):939-47 [9214673.001]
  • [Cites] Pediatr Clin North Am. 1997 Aug;44(4):831-46 [9286287.001]
  • [Cites] Environ Health Perspect. 1997 Oct;105(10):1068-77 [9349828.001]
  • [Cites] J Natl Cancer Inst. 1999 Oct 20;91(20):1765-72 [10528028.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(4):813-23 [10673523.001]
  • [Cites] Curr Opin Oncol. 2000 Jan;12(1):3-12 [10687723.001]
  • [Cites] Am J Epidemiol. 2000 Mar 1;151(5):512-5 [10707920.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] Br J Cancer. 2000 Sep;83(5):692-8 [10944614.001]
  • [Cites] Am J Epidemiol. 2000 Sep 1;152(5):480-6 [10981463.001]
  • [Cites] Epidemiology. 2000 Nov;11(6):624-34 [11055621.001]
  • [CommentIn] Environ Health Perspect. 2007 Aug;115(8):A395-6 [17687418.001]
  • [CommentIn] Environ Health Perspect. 2007 Aug;115(8):A395 [17687419.001]
  • [ErratumIn] Environ Health Perspect. 2010 Sep;118(9):A380
  • (PMID = 17366834.001).
  • [ISSN] 0091-6765
  • [Journal-full-title] Environmental health perspectives
  • [ISO-abbreviation] Environ. Health Perspect.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 145
  • [Other-IDs] NLM/ PMC1817663
  •  go-up   go-down


30. Singh H, Prasad BN, Jagdish, Batra A: Hyperleukocytosis associated pulmonary leukostasis in acute leukaemia. J Assoc Physicians India; 2006 May;54:405-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hyperleukocytosis associated pulmonary leukostasis in acute leukaemia.
  • Leukostasis is a fatal complication in granulocytic leukaemia.
  • In the lung, the clinical presentation simulates infections and haemorrhagic complications of acute leukaemia.
  • [MeSH-major] Leukemia / complications. Leukocytosis / etiology. Leukostasis / etiology. Lung Diseases / etiology

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16909741.001).
  • [ISSN] 0004-5772
  • [Journal-full-title] The Journal of the Association of Physicians of India
  • [ISO-abbreviation] J Assoc Physicians India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


31. Kan JH, Hernanz-Schulman M, Frangoul HA, Connolly SA: MRI diagnosis of bone marrow relapse in children with ALL. Pediatr Radiol; 2008 Jan;38(1):76-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MRI diagnosis of bone marrow relapse in children with ALL.
  • BACKGROUND: Diffuse marrow replacement in acute leukemia is well known, but there are few reports describing the MRI features of pediatric leukemic relapse.
  • From this group, 14 children seen at initial diagnosis of leukemia and 2 children who underwent MRI after therapy for relapse were excluded.
  • Images of patients with relapse and in remission were reviewed for type and configuration of marrow infiltration; coexisting marrow alterations including osteonecrosis or stress reaction were also reviewed.
  • CONCLUSION: Well-defined nodules in all patients with leukemic relapse suggest that this appearance is characteristic and distinct from the published findings of diffuse marrow replacement in acute leukemia.
  • [MeSH-major] Bone Marrow Diseases / diagnosis. Magnetic Resonance Imaging / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Male. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Bone Marrow Diseases.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Paediatr Scand Suppl. 1974;(252):1-20 [4618418.001]
  • [Cites] Acta Paediatr Scand. 1981 Nov;70(6):879-83 [7324941.001]
  • [Cites] J Urol. 1991 Aug;146(2 ( Pt 2)):665-8 [1861322.001]
  • [Cites] Semin Nucl Med. 1992 Apr;22(2):98-111 [1317065.001]
  • [Cites] Acta Paediatr Scand. 1989 Nov;78(6):923-9 [2557721.001]
  • [Cites] Radiology. 1986 Jul;160(1):237-40 [3459212.001]
  • [Cites] Arch Dis Child. 2003 Aug;88(8):688-94 [12876164.001]
  • [Cites] J Urol. 2004 Sep;172(3):1071-3; discussion 1073-4 [15311040.001]
  • [Cites] Pediatr Radiol. 2006 Nov;36(11):1119-32; quiz 1228-9 [16791588.001]
  • [Cites] Pediatrics. 2000 Jun;105(6):1236-41 [10835063.001]
  • [Cites] J Urol. 1988 Nov;140(5 Pt 2):1169-74 [2846898.001]
  • [Cites] J Urol. 1983 Jun;129(6):1102-6 [6343637.001]
  • [Cites] J Urol. 2003 Oct;170(4 Pt 2):1548-50 [14501657.001]
  • [Cites] J Urol. 1999 Jun;161(6):1928-33 [10332475.001]
  • [Cites] J Urol. 1992 Nov;148(5 Pt 2):1743-5 [1433600.001]
  • [Cites] J Pediatr. 1993 Oct;123(4):559-63 [8410507.001]
  • [Cites] Radiology. 1991 Nov;181(2):587-9 [1924809.001]
  • [Cites] J Urol. 2004 Sep;172(3):1075-7; discussion 1077 [15311041.001]
  • [Cites] N Z Med J. 1995 Apr 26;108(998):142-4 [7761049.001]
  • [Cites] Pediatr Nephrol. 1993 Aug;7(4):361-4 [8398641.001]
  • [Cites] J Pediatr. 2000 Jan;136(1):30-4 [10636970.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3066-72 [11408503.001]
  • [Cites] Arch Dis Child. 1995 May;72 (5):393-6 [7618903.001]
  • [Cites] Radiology. 1998 May;207 (2):377-84 [9577484.001]
  • [Cites] J Urol. 1996 May;155(5):1711-5 [8627867.001]
  • [Cites] Arch Dis Child Fetal Neonatal Ed. 1994 Mar;70(2):F147-9; discussion 149-50 [7802758.001]
  • [Cites] BJU Int. 2000 Jul;86(1):94-6 [10886091.001]
  • [Cites] Nephron. 1982;30(3):262-8 [7099339.001]
  • [Cites] Pediatr Radiol. 1990;20(3):179-83 [2352796.001]
  • [Cites] J Urol. 1987 Oct;138(4 Pt 2):941-6 [3656575.001]
  • [Cites] Lancet. 1973 Jul 7;2(7819):1-4 [4123292.001]
  • [Cites] Pediatr Radiol. 1990;20(4):272-6 [2336289.001]
  • [Cites] Am J Hematol. 2004 Jul;76(3):279-82 [15224367.001]
  • [Cites] Arch Dis Child. 1991 Nov;66(11):1282-3 [1661570.001]
  • [Cites] J Urol. 1998 Sep;160(3 Pt 2):1019-22 [9719268.001]
  • [Cites] J Urol. 1975 Aug;114(2):274-80 [1171997.001]
  • [Cites] Clin Radiol. 1960 Oct;11:219-31 [13714877.001]
  • [Cites] Pediatr Nephrol. 1997 Feb;11(1):108-20 [9035184.001]
  • [Cites] BMJ. 1994 May 7;308(6938):1193-6 [8180534.001]
  • [Cites] Urology. 1999 Apr;53(4):812-5 [10197863.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1387-95 [9529033.001]
  • [Cites] J Urol. 2006 Oct;176(4 Pt 2):1786-92 [16945650.001]
  • [Cites] J Urol. 2005 Mar;173(3):697-704 [15711246.001]
  • [Cites] Pediatrics. 2006 Mar;117(3):626-32 [16510640.001]
  • [Cites] Clin Nephrol. 1973 May-Jun;1(3):132-41 [4783715.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] J Urol. 1992 Nov;148(5 Pt 2):1674-5 [1433586.001]
  • [Cites] J Urol. 2000 Nov;164(5):1674-8; discussion 1678-9 [11025746.001]
  • [Cites] Br Med J. 1965 Apr 17;1(5441):1023-6 [14262192.001]
  • [Cites] J Urol. 2005 Feb;173(2):571-4; discussion 574-5 [15643259.001]
  • [Cites] Infect Dis Clin North Am. 1987 Dec;1(4):713-29 [3333655.001]
  • [Cites] Curr Probl Pediatr Adolesc Health Care. 2002 Feb;32(2):40-9 [11951089.001]
  • [Cites] J Urol. 1976 Oct;116(4):503-5 [1053345.001]
  • [Cites] Radiology. 1991 Jan;178(1):193-6 [1984303.001]
  • [Cites] Br J Haematol. 2005 Apr;129(2):163 [15813842.001]
  • [Cites] Pediatrics. 1999 Apr;103(4 Pt 1):843-52 [10103321.001]
  • [Cites] Pediatr Nephrol. 1998 Nov;12 (9):727-36 [9874316.001]
  • [Cites] J Am Soc Nephrol. 2003 Mar;14 (3):739-44 [12595511.001]
  • [Cites] J Pediatr. 1996 Jan;128(1):15-22 [8551409.001]
  • [Cites] J Urol. 1992 Nov;148(5 Pt 2):1653-6 [1433582.001]
  • [Cites] Pediatr Nephrol. 2006 Jun;21(6):785-92 [16565873.001]
  • (PMID = 17994232.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


32. Sandoval C, Pine SR, Guo Q, Sastry S, Stewart J, Kronn D, Jayabose S: Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature. Pediatr Blood Cancer; 2005 Jan;44(1):85-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
  • Infants with constitutional trisomy 21 are at increased risk of developing transient and acute megakaryoblastic leukemia (AMKL).
  • Mutations in GATA1 have been identified in trisomy 21 patients with AMKL, and this lesion is thought to be an initial event by virtue of its presence during transient leukemia.
  • Transient leukemia is also observed in phenotypically normal infants albeit much less commonly so.
  • Almost all these infants are mosaic for trisomy 21, and the clinical course of transient leukemia recapitulates that observed in constitutional trisomy 21.
  • We report a phenotypically normal infant with tetrasomy 21 transient leukemia, GATA1 mutation within exon 2, and trisomy 21 mosaicism restricted to the hematopoietic tissue.
  • Two years after diagnosis, low levels of trisomy 21 persisted in the peripheral blood, which resolved 2.5 years after diagnosis.
  • The literature review identified 32 phenotypically normal infants with transient leukemia.
  • Ninety-one percent (29 of 32) were observed and three received chemotherapy at diagnosis of transient leukemia.
  • Nineteen percent (6 of 32) developed acute leukemia, and four continued in remission (two died).
  • Transient leukemia in trisomy 21 mosaicism recapitulates the condition observed in constitutional trisomy 21 at the biological and clinical levels.
  • Infants should be followed for the development of acute leukemia.
  • [MeSH-major] DNA-Binding Proteins / genetics. Down Syndrome / genetics. Leukemia, Megakaryoblastic, Acute / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Down Syndrome.
  • The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for tetrasomy 21 .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15390279.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Erythroid-Specific DNA-Binding Factors; 0 / GATA1 Transcription Factor; 0 / GATA1 protein, human; 0 / Transcription Factors
  • [Number-of-references] 46
  •  go-up   go-down


33. Pascoe J, Cullen M: The prevention of febrile neutropenia. Curr Opin Oncol; 2006 Jul;18(4):325-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Recent research confirms that prophylactic antibiotics decrease febrile neutropenia and infection-related mortality in acute leukaemia patients and those receiving high dose chemotherapy.
  • SUMMARY: Antibiotic prophylaxis should be offered to patients receiving chemotherapy for acute leukaemia and high dose chemotherapy for solid tumours.

  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16721125.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antineoplastic Agents; 0 / Fluoroquinolones; 143011-72-7 / Granulocyte Colony-Stimulating Factor
  • [Number-of-references] 28
  •  go-up   go-down


34. Gros F, Sebti Y, de Guibert S, Branger B, Bernard M, Fauchet R, Amiot L: Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages. Neoplasia; 2006 Mar;8(3):223-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soluble HLA-G molecules increase during acute leukemia, especially in subtypes affecting monocytic and lymphoid lineages.
  • Assay of these molecules by enzyme-linked immunosorbent assay in patients suffering from another hematologic disorder (acute leukemia) highlights increased sHLA-G secretion.
  • This increased secretion seems more marked in acute leukemia subtypes affecting monocytic and lymphoid lineages such as FABM4 and FABM5, as well as both B and T acute lymphoblastic leukemia (ALL).
  • All these findings suggest that sHLA-G molecules could be a factor in tumoral escape from immune survey during acute leukemia.
  • [MeSH-major] Antigens, Neoplasm / blood. HLA Antigens / blood. Histocompatibility Antigens Class I / blood. Leukemia / blood
  • [MeSH-minor] Acute Disease. Biomarkers, Tumor / blood. Burkitt Lymphoma / blood. Burkitt Lymphoma / genetics. Burkitt Lymphoma / metabolism. Burkitt Lymphoma / pathology. Cell Line, Tumor / chemistry. Cell Line, Tumor / drug effects. Cell Line, Tumor / metabolism. Cytokines / blood. Cytokines / pharmacology. Enzyme-Linked Immunosorbent Assay. Gene Expression Regulation, Leukemic / drug effects. HLA-G Antigens. Humans. Leukemia, Myeloid / blood. Leukemia, Myeloid / classification. Leukemia, Myeloid / genetics. Leukemia, Myeloid / metabolism. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / blood. Leukemia-Lymphoma, Adult T-Cell / genetics. Leukemia-Lymphoma, Adult T-Cell / metabolism. Leukemia-Lymphoma, Adult T-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Retrospective Studies. Solubility. Tumor Escape

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol. 2000 Jun 15;164(12):6100-4 [10843658.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):379-85 [14708718.001]
  • [Cites] Br J Haematol. 2000 Oct;111(1):280-2 [11091213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1102-7 [11137213.001]
  • [Cites] Hum Immunol. 2000 Nov;61(11):1138-49 [11137219.001]
  • [Cites] Hum Immunol. 2000 Dec;61(12):1347-51 [11163092.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6133-9 [11087747.001]
  • [Cites] Cancer. 2001 Jul 15;92(2):369-76 [11466692.001]
  • [Cites] Am J Pathol. 2001 Sep;159(3):817-24 [11549573.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6838-45 [11559559.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12150-5 [11572934.001]
  • [Cites] Nephrologie. 2003;24(8):451-6 [14737978.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Dec;84(24):9145-9 [3480534.001]
  • [Cites] Science. 1990 Apr 13;248(4952):220-3 [2326636.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 May 1;89(9):3947-51 [1570318.001]
  • [Cites] Cell Immunol. 1994 May;155(2):312-22 [8181068.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 May 10;91(10):4209-13 [8183892.001]
  • [Cites] J Immunol. 1994 Dec 15;153(12):5516-24 [7989753.001]
  • [Cites] Tissue Antigens. 1996 Nov;48(5):609-14 [8988550.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 13;94(10):5249-54 [9144223.001]
  • [Cites] J Exp Med. 1997 Jul 21;186(2):289-98 [9221758.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Oct 14;94(21):11520-5 [9326642.001]
  • [Cites] Eur J Immunol. 1997 Dec;27(12):3380-8 [9464826.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4510-5 [9539768.001]
  • [Cites] Blood. 2002 Jan 15;99(2):609-17 [11781245.001]
  • [Cites] J Pathol. 2002 Mar;196(3):266-74 [11857488.001]
  • [Cites] Eur J Immunol. 1998 Jun;28(6):1980-90 [9645380.001]
  • [Cites] Hum Immunol. 1998 Aug;59(8):524-8 [9712358.001]
  • [Cites] Eur J Immunol. 1999 Jan;29(1):277-83 [9933109.001]
  • [Cites] Tissue Antigens. 1999 Jan;53(1):14-22 [10082427.001]
  • [Cites] Int Immunol. 1999 May;11(5):803-11 [10330285.001]
  • [Cites] Am J Reprod Immunol. 1999 Jul;42(1):30-6 [10429764.001]
  • [Cites] J Reprod Immunol. 1999 Jul;43(2):105-9 [10479047.001]
  • [Cites] Autoimmun Rev. 2005 Nov;4(8):503-9 [16214086.001]
  • [Cites] Hum Immunol. 2005 Aug;66(8):853-63 [16216668.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4772-80 [11971028.001]
  • [Cites] J Clin Invest. 2002 Nov;110(10):1515-23 [12438449.001]
  • [Cites] Eur J Immunol. 2002 Dec;32(12):3576-86 [12516543.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1191-6 [12552087.001]
  • [Cites] Eur J Immunol. 2003 Jan;33(1):125-34 [12594841.001]
  • [Cites] Leuk Res. 2003 Jul;27(7):643-8 [12681364.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):752-61 [12878353.001]
  • [Cites] Hum Immunol. 2003 Aug;64(8):802-10 [12878359.001]
  • [Cites] Clin Cancer Res. 2003 Oct 1;9(12):4460-4 [14555519.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1017-24 [14602230.001]
  • [Cites] Hum Immunol. 2003 Nov;64(11):1093-101 [14602240.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jan 16;313(3):606-11 [14697234.001]
  • [Cites] Semin Cancer Biol. 2003 Oct;13(5):343-51 [14708714.001]
  • [Cites] Ann Neurol. 2000 Oct;48(4):679-84 [11026456.001]
  • (PMID = 16611416.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  • [Other-IDs] NLM/ PMC1578523
  •  go-up   go-down


35. Li XL, Sun LR: [Effect of muramyl dipeptide on proliferation of dendritic cells derived from children acute leukemia bone marrow in vitro]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug;18(4):963-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of muramyl dipeptide on proliferation of dendritic cells derived from children acute leukemia bone marrow in vitro].
  • The aim of this study was to explore the effect of muramyl dipeptide (MDP) on proliferation of dendritic cells (DCs) from bone marrow of children with acute leukemia in vitro.
  • The mononuclear cells were isolated from bone marrow of children with acute leukemia to induce dendritic cells.
  • It is concluded that MDP not only promotes the proliferation of DCs derived from bone marrow of children with acute leukemia in vitro, cooperates with rhGM-CSF, rhIL-4 and rhTNFalpha in promoting of the proliferation and maturation of DCs, while the promotive effect of MDP alone on the proliferation of DCs is not as good as its combination with cytokines.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20723309.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 53678-77-6 / Acetylmuramyl-Alanyl-Isoglutamine
  •  go-up   go-down


36. Terzakis JA, Santagada E, Hernandez A, Taskin M: Scanning electron microscopy of peripheral blood smears: comparison of normal blood with some common leukemias. Ultrastruct Pathol; 2005 Jan-Feb;29(1):19-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Scanning electron microscopy of peripheral blood smears: comparison of normal blood with some common leukemias.
  • Peripheral blood smears prepared routinely from nonneoplastic and leukemia cases were studied using the scanning electron microscope (SEM).
  • The peripheral blood glass slide is examined directly in the SEM following application of a thin carbon coat.
  • The morphology of the nonneoplastic and neoplastic smears is described in detail utilizing the SEM secondary electron detector and backscattered electron detectors.
  • Certain cell features are measured as well with the use of the measuring software resident in the SEM.
  • The problem of cell constituent loss and overall shrinkage in the routinely processed and sectioned material is noted.
  • The monoblast resembles the normal monocyte but both cell size and nuclear size are greater; the moderately reticulated nuclear chromatin distinguishes the monoblast.
  • The neoplastic lymphoid cell shows coarse clumping of nuclear chromatin and in some instances coarse chromatin anastomoses to distinguish it from the normal lymphocyte.
  • Lymphoid cells of acute lymphoblastic leukemia are 33% larger than those of chronic lymphocytic leukemia and normal lymphocytes.
  • A candidate for such a cell is recognized morphologically as well.
  • [MeSH-major] Blood Cells / pathology. Blood Cells / ultrastructure. Cytodiagnosis. Leukemia / diagnosis. Microscopy, Electron, Scanning
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Size. Female. Flow Cytometry. Humans. Male. Middle Aged. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15931777.001).
  • [ISSN] 0191-3123
  • [Journal-full-title] Ultrastructural pathology
  • [ISO-abbreviation] Ultrastruct Pathol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Agarwal R, Gupta R, Bakhshi S, Sharma A: Unusual cytochemical reactivity for toluidine blue in granular acute lymphoblastic leukemia: a report of two rare cases. Turk J Haematol; 2010 Mar 5;27(1):43-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual cytochemical reactivity for toluidine blue in granular acute lymphoblastic leukemia: a report of two rare cases.
  • [Transliterated title] Granüler akut lenfoblastik lösemide toluidin mavisine yönelik olağandışı sitokimyasal reaktivite: İki nadir olgu raporu.
  • Azurophilic granulation of blasts is a feature of acute myeloid leukemia (AML).
  • Granular acute lymphoblastic leukemia (ALL) may mimic AML due to the presence of cytoplasmic granules in lymphoblasts, but cytochemistry and immunophenotyping are helpful in making the correct diagnosis.
  • Immunophenotyping and cytogenetic studies were helpful in making a correct diagnosis.
  • This report of two rare case highlight the reactivity of lymphoblasts with TB not hitherto described and the importance of a detailed diagnostic work-up in acute leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27265798.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


38. Ma SL, Sørensen AB, Kunder S, Sørensen KD, Quintanilla-Martinez L, Morris DW, Schmidt J, Pedersen FS: The Icsbp locus is a common proviral insertion site in mature B-cell lymphomas/plasmacytomas induced by exogenous murine leukemia virus. Virology; 2006 Sep 1;352(2):306-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Icsbp locus is a common proviral insertion site in mature B-cell lymphomas/plasmacytomas induced by exogenous murine leukemia virus.
  • ICSBP (interferon consensus sequence binding protein)/IRF8 (interferon regulatory factor 8) is an interferon gamma-inducible transcription factor expressed predominantly in hematopoietic cells, and down-regulation of this factor has been observed in chronic myelogenous leukemia and acute myeloid leukemia in man.
  • By screening about 1200 murine leukemia virus (MLV)-induced lymphomas, we found proviral insertions at the Icsbp locus in 14 tumors, 13 of which were mature B-cell lymphomas or plasmacytomas.
  • Only one was a T-cell lymphoma, although such tumors constituted about half of the samples screened.
  • Interestingly, proviral insertions at Icsbp have not been reported from previous extensive screenings of mature B-cell lymphomas induced by endogenous MLvs. We propose that ICSBP might be involved in an early modulation of an immune response to exogenous MLVs that might also play a role in proliferation of the mature B-cell lymphomas.
  • [MeSH-major] Interferon Regulatory Factors / genetics. Leukemia Virus, Murine / genetics. Leukemia Virus, Murine / pathogenicity. Lymphoma, B-Cell / virology. Plasmacytoma / virology. Virus Integration / genetics

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780917.001).
  • [ISSN] 0042-6822
  • [Journal-full-title] Virology
  • [ISO-abbreviation] Virology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon Regulatory Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / interferon regulatory factor-8
  •  go-up   go-down


39. Van Belle W, Anensen N, Haaland I, Bruserud Ø, Høgda KA, Gjertsen BT: Correlation analysis of two-dimensional gel electrophoretic protein patterns and biological variables. BMC Bioinformatics; 2006;7:198
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This often proves time consuming and difficult when working with non-perfect gels.
  • Since p53 is altered through these signaling networks, we expected to find correlations between the cancer type (acute lymphoblastic leukemia and acute myeloid leukemia) and the p53 profiles.
  • A second correlation analysis revealed a more complex relation between the differentiation stage in acute myeloid leukemia and p53 protein isoforms.
  • [MeSH-major] Biomarkers, Tumor / analysis. Electrophoresis, Gel, Two-Dimensional / methods. Gene Expression Profiling / methods. Leukemia / metabolism. Neoplasm Proteins / analysis. Protein Processing, Post-Translational. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Electrophoresis. 2005 Jun;26(12):2461-9 [15924363.001]
  • [Cites] Eur J Haematol. 2001 Mar;66(3):178-87 [11350486.001]
  • [Cites] J Hematother Stem Cell Res. 2002 Jun;11(3):469-81 [12183832.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2002;:162-92 [12446423.001]
  • [Cites] Nature. 2003 Mar 13;422(6928):226-32 [12634796.001]
  • [Cites] Haematologica. 2003 Apr;88(4):416-28 [12681969.001]
  • [Cites] Expert Rev Mol Diagn. 2003 Jul;3(4):411-20 [12877381.001]
  • [Cites] Leukemia. 2003 Aug;17(8):1605-12 [12886250.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1617-28 [15084694.001]
  • [Cites] Trends Mol Med. 2004 Mar;10(3):113-8 [15102353.001]
  • [Cites] Biochem Soc Trans. 2004 Jun;32(Pt3):511-6 [15157174.001]
  • [Cites] Scand J Immunol. 2004 Jul-Aug;60(1-2):189-98 [15238089.001]
  • [Cites] Cell. 2004 Jul 23;118(2):217-28 [15260991.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6887-96 [15501966.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):793-805 [15510160.001]
  • [Cites] J Biol Chem. 1975 May 25;250(10):4007-21 [236308.001]
  • [Cites] Br J Haematol. 1976 Aug;33(4):451-8 [188440.001]
  • [Cites] J Biol Chem. 1979 Aug 25;254(16):7961-77 [468801.001]
  • [Cites] Proc Natl Acad Sci U S A. 1983 Oct;80(19):5919-22 [6351070.001]
  • [Cites] Br J Haematol. 1991 Jul;78(3):325-9 [1651754.001]
  • [Cites] Electrophoresis. 1991 Oct;12(10):722-35 [1802690.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2230-7 [8161788.001]
  • [Cites] Electrophoresis. 1995 Mar;16(3):298-305 [7607160.001]
  • [Cites] J Biol Chem. 1995 Sep 1;270(35):20599-607 [7657638.001]
  • [Cites] Leukemia. 1995 Oct;9(10):1783-6 [7564526.001]
  • [Cites] N Engl J Med. 2004 Apr 15;350(16):1605-16 [15084693.001]
  • [Cites] Br J Haematol. 1996 Mar;92(4):929-36 [8616087.001]
  • [Cites] Cell Signal. 1998 Mar;10(3):159-66 [9607138.001]
  • [Cites] Br J Cancer. 1998 May;77(9):1429-38 [9652758.001]
  • [Cites] Blood. 1998 Oct 1;92(7):2322-33 [9746770.001]
  • [Cites] Br J Haematol. 1999 Oct;107(1):69-79 [10520026.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:80-97 [15561678.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2004;:98-117 [15561679.001]
  • [Cites] Proteomics. 2004 Dec;4(12):3665-85 [15543535.001]
  • [Cites] Nat Cell Biol. 2005 Feb;7(2):165-71 [15619621.001]
  • [Cites] Mol Cell Proteomics. 2005 Apr;4(4):492-522 [15695426.001]
  • [Cites] Oncogene. 2005 Apr 18;24(17):2899-908 [15838523.001]
  • [Cites] Haematologica. 2005 Jul;90(7):949-68 [15996933.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):233-48 [16029452.001]
  • [Cites] J Clin Oncol. 2005 Aug 10;23(23):5386-403 [15983388.001]
  • [Cites] Genes Dev. 2005 Sep 15;19(18):2122-37 [16131611.001]
  • [Cites] Curr Drug Targets. 2005 Sep;6(6):631-46 [16178797.001]
  • [Cites] Electrophoresis. 2006 Oct;27(20):4086-95 [16983632.001]
  • [Cites] Leukemia. 2000 Jul;14(7):1292-300 [10914555.001]
  • (PMID = 16606449.001).
  • [ISSN] 1471-2105
  • [Journal-full-title] BMC bioinformatics
  • [ISO-abbreviation] BMC Bioinformatics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Protein p53
  • [Other-IDs] NLM/ PMC1559651
  •  go-up   go-down


40. Ragu C, Boukour S, Elain G, Wagner-Ballon O, Raslova H, Debili N, Olson EN, Daegelen D, Vainchenker W, Bernard OA, Penard-Lacronique V: The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development. Leukemia; 2010 Jun;24(6):1227-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The serum response factor (SRF)/megakaryocytic acute leukemia (MAL) network participates in megakaryocyte development.
  • [MeSH-major] Leukemia, Megakaryoblastic, Acute / pathology. Megakaryocytes / cytology. Megakaryocytes / metabolism. Serum Response Factor / physiology. Trans-Activators / physiology

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20428204.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Letter; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / MKL1 protein, mouse; 0 / Serum Response Factor; 0 / Trans-Activators; EC 2.7.7.- / Cre recombinase; EC 2.7.7.- / Integrases
  •  go-up   go-down


41. Onnebo SM, Condron MM, McPhee DO, Lieschke GJ, Ward AC: Hematopoietic perturbation in zebrafish expressing a tel-jak2a fusion. Exp Hematol; 2005 Feb;33(2):182-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Various TEL-JAK2 fusions have been identified in patients with lymphoblastic and myeloid leukemias that result in constitutive activation of the JAK2 kinase domain.
  • Such fusions can mediate factor-independent growth of hematopoietic cell lines and induction of malignancy in mouse models.
  • MATERIALS AND METHODS: To assess whether zebrafish could be utilized as a suitable model for the study of myeloid oncogenesis, we generated a zebrafish tel-jak2a fusion oncoprotein based on that seen in a case of chronic myeloid leukemia.
  • RESULTS: Visual, histological, and molecular analysis revealed disruption of normal embryonic hematopoiesis, including perturbation of the myeloid and erythroid lineages.
  • [MeSH-major] DNA-Binding Proteins / genetics. Hematopoiesis / physiology. Leukemia, Myeloid / genetics. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics. Repressor Proteins / genetics
  • [MeSH-minor] Acute Disease. Amino Acid Sequence. Animals. Animals, Genetically Modified. Disease Models, Animal. Embryo, Nonmammalian / physiology. Janus Kinase 2. Peptide Fragments / chemistry. Proto-Oncogene Proteins c-ets. Recombinant Fusion Proteins / metabolism. Zebrafish

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • ZFIN. ZFIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15676212.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / ETS translocation variant 6 protein; 0 / Peptide Fragments; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-ets; 0 / Recombinant Fusion Proteins; 0 / Repressor Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / Jak2 protein, mouse; EC 2.7.10.2 / Janus Kinase 2
  •  go-up   go-down


42. Abstracts from Acute Leukemias XI. Prognostic Factors and Treatment Strategies. February 18-22, 2006. Munich, Germany. Ann Hematol; 2006;85 Suppl 1:12-126
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abstracts from Acute Leukemias XI. Prognostic Factors and Treatment Strategies. February 18-22, 2006. Munich, Germany.
  • [MeSH-major] Acute Disease / therapy
  • [MeSH-minor] Animals. Humans. Leukemia. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16456698.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Congresses; Overall
  • [Publication-country] Germany
  •  go-up   go-down


43. Dalle F, Lafon I, L'ollivier C, Ferrant E, Sicard P, Labruère C, Jebrane A, Laubriet A, Vagner O, Caillot D, Bonnin A: A prospective analysis of the genotypic diversity and dynamics of the Candida albicans colonizing flora in neutropenic patients with de novo acute leukemia. Haematologica; 2008 Apr;93(4):581-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective analysis of the genotypic diversity and dynamics of the Candida albicans colonizing flora in neutropenic patients with de novo acute leukemia.
  • We report the result of a prospective study aimed at investigating the dynamics and heterogeneity of C. albicans flora in patients with de novo acute leukemia.
  • DESIGN AND METHODS: Between 2001 and 2003, 66 consecutive adults with newly diagnosed acute leukemia were monitored for Candida colonization.
  • CONCLUSIONS: In patients with de novo acute leukemia, genetic evolution of the colonizing C. albicans flora and selection of variants or replacement of the original strain upon antifungal drug pressure or nosocomial transmission are rare events.
  • [MeSH-major] Candida albicans / genetics. Candidiasis / microbiology. Genome, Fungal. Leukemia / complications. Neutropenia / complications
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Aged, 80 and over. Antifungal Agents / pharmacology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Drug Resistance, Fungal / genetics. Female. Genetic Variation. Genotype. Humans. Immunocompromised Host. Male. Middle Aged. Myeloablative Agonists / adverse effects. Myeloablative Agonists / therapeutic use. Organ Specificity. Patient Isolation. Sampling Studies

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18322258.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Myeloablative Agonists
  •  go-up   go-down


44. Li X, Du W, Liu W, Li X, Li H, Huang SA: Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse. APMIS; 2010 May;118(5):353-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive flow cytometry phenotype in acute leukemia at diagnosis and at relapse.
  • Multiparameter flow cytometry (MFC) plays a vital role in the detection of minimal residual disease (MRD) and diagnosis of relapse in acute leukemia.
  • However, application of a limited panel of antibodies in MFC leads to high rates of false-negative and false-positive results.
  • Thirteen patients with acute lymphoblastic leukemia (ALL) and 12 patients with acute myeloid leukemia (AML) were immunophenotyped by MFC at diagnosis and at relapse using a comprehensive panel of monoclonal antibodies (McAbs) to 27 antigens and CD45/SSC gating.
  • In 23 of 25 patients (92.3%), changes in at least one of progenitor-associated, myeloid and lymphoid antigens between diagnosis and relapse were observed.
  • Multiple panels of three or more McAbs are likely to be required in the monitoring of MRD and diagnosis of relapse in acute leukemia by MFC.
  • [MeSH-major] Flow Cytometry / methods. Immunophenotyping / methods. Leukemia, Myeloid, Acute / diagnosis. Leukemia, Myeloid, Acute / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20477810.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD; 0 / Antigens, Neoplasm
  •  go-up   go-down


45. Cong W, Liu Q, Chen X, Gao R, Lu J, Wang Y, Luo G: Characterization and pharmacokinetics of a novel pirarubicin liposome powder. Drug Dev Ind Pharm; 2010 Oct;36(10):1186-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characterization and pharmacokinetics of a novel pirarubicin liposome powder.
  • BACKGROUND: Pirarubicin (THP), an analogue of doxorubicin, has exhibited promising activities against acute leukemia, malignant lymphoma, and several solid tumors.

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20515395.001).
  • [ISSN] 1520-5762
  • [Journal-full-title] Drug development and industrial pharmacy
  • [ISO-abbreviation] Drug Dev Ind Pharm
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Carriers; 0 / Excipients; 0 / Liposomes; 0 / Powders; 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


46. Jiang SH, Ma XD, Huang YQ, Xu YL, Zheng RJ: [Phenylhexyl isothiocyanate induces gene p15 demethylation by down-regulating DNA methyltransferases in Molt-4 cells]. Yao Xue Xue Bao; 2009 Apr;44(4):350-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study is to investigate the effect of phenylhexyl isothiocyanate (PHI), which has been proved to be a novel histone deacetylase inhibitor (HDACi) recently, on gene p15 de novo expression in acute leukemia cell line Molt-4, and to further study its potential mechanism.
  • Hypermethylation of gene p15 was reversed and activation transcription of gene p15 in Molt-4 was de novo after 5 days exposure to PHI in a concentration dependent manner.
  • It is showed that PHI could reverse hypermethylation of gene p15 and transcriptional activation of gene p15 is de novo by PHI.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p15 / genetics. DNA (Cytosine-5-)-Methyltransferase / metabolism. DNA Methylation. Isothiocyanates / pharmacology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Cell Line, Tumor. Histone Deacetylase Inhibitors / pharmacology. Humans. RNA, Messenger / metabolism. Repressor Proteins / genetics. Repressor Proteins / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19545050.001).
  • [ISSN] 0513-4870
  • [Journal-full-title] Yao xue xue bao = Acta pharmaceutica Sinica
  • [ISO-abbreviation] Yao Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / DMAP1 protein, human; 0 / Histone Deacetylase Inhibitors; 0 / Isothiocyanates; 0 / RNA, Messenger; 0 / Repressor Proteins; 133920-06-6 / 6-phenylhexyl isothiocyanate; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA methyltransferase 3A; EC 2.1.1.37 / DNA methyltransferase 3B
  •  go-up   go-down


47. Drumea K, Yang ZF, Rosmarin A: Retinoic acid signaling in myelopoiesis. Curr Opin Hematol; 2008 Jan;15(1):37-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Currently, retinoic acid is a front-line agent in the treatment of certain forms of acute myelogenous leukemia.
  • In this review, we focus on recent advances in our understanding of the mechanisms by which retinoids affect growth and proliferation of myeloid cells and contribute to the pathogenesis of leukemia.
  • Important advances regarding cell biology, molecular biology, biochemistry, and animal studies of retinoids and myeloid differentiation are reviewed.
  • SUMMARY: Greater understanding of the role of retinoids and their receptors in myeloid cell growth and differentiation provides important insight into normal myelopoiesis.
  • These findings have resulted in successful rational approaches to the treatment of acute leukemia and provide the promise of improved treatments in the near future.
  • [MeSH-minor] Animals. Cell Differentiation / drug effects. Cell Transformation, Neoplastic. Chromatin / genetics. Chromatin / metabolism. Gene Expression Regulation / physiology. Humans. Leukemia, Myeloid / pathology. Leukemia, Promyelocytic, Acute / drug therapy. Leukemia, Promyelocytic, Acute / genetics. Mice. Myeloid Cells / cytology. Myeloid Cells / drug effects. Myeloproliferative Disorders / pathology. Oncogene Proteins, Fusion / metabolism. Protein Processing, Post-Translational. Receptors, Retinoic Acid / drug effects. Receptors, Retinoic Acid / physiology. Retinoids / physiology. Signal Transduction. Transcription Factors / metabolism

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043244.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1P20 RR 017695; United States / NCRR NIH HHS / RR / 1P20 RR 018757; United States / NHLBI NIH HHS / HL / 1R01 HL 073945; United States / NCRR NIH HHS / RR / P20 RR 15578
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromatin; 0 / Oncogene Proteins, Fusion; 0 / Receptors, Retinoic Acid; 0 / Retinoids; 0 / Transcription Factors; 5688UTC01R / Tretinoin
  • [Number-of-references] 34
  •  go-up   go-down


48. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P: Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost; 2006 Jun;32(4 Pt 2):417-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite recent discoveries made in myeloproliferative disorders other than chronic myelogenous leukemia, which it is hoped will result in earlier diagnosis, and better evaluation and management of patients, hematological evolution to myelofibrosis, acute leukemia, and myelodysplastic syndromes (AL/MDS) remain major causes of long-term mortality in polycythemia vera (PV) and essential thrombocythemia (ET) patients.
  • The results show that the incidence of AL/MDS is higher than previously reported with no evidence of a plateau (with approximately 40% of AL/MDS cases occurring after the 12th year of follow-up).
  • Although hydroxyurea currently remains the first choice in the treatment of high-risk PV and ET patients, the use of nonleukemogenic drugs, such as interferon alpha (IFN-alpha) or anagrelide, should be assessed more widely in randomized trials using accurate diagnostic criteria and taking into account the presence of the JAK2 mutation, given that they may have an impact on disease evolution.
  • [MeSH-minor] Drug Therapy, Combination. Female. Humans. Interferon-alpha / adverse effects. Interferon-alpha / therapeutic use. Janus Kinase 2. Leukemia / chemically induced. Leukemia / etiology. Male. Mutation. Myelodysplastic Syndromes / chemically induced. Myelodysplastic Syndromes / etiology. Prospective Studies. Protein-Tyrosine Kinases / genetics. Proto-Oncogene Proteins / genetics. Randomized Controlled Trials as Topic. Retrospective Studies. Time Factors

  • Genetic Alliance. consumer health - Essential Thrombocythemia.
  • Genetic Alliance. consumer health - Polycythemia vera.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. PIPOBROMAN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810617.001).
  • [ISSN] 0094-6176
  • [Journal-full-title] Seminars in thrombosis and hemostasis
  • [ISO-abbreviation] Semin. Thromb. Hemost.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Interferon-alpha; 0 / Proto-Oncogene Proteins; 6Q99RDT97R / Pipobroman; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.2 / JAK2 protein, human; EC 2.7.10.2 / Janus Kinase 2; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 42
  •  go-up   go-down


49. Hur M, Park JY, Cho HC, Lee KM, Shin HY, Cho HI: Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population. Clin Lab Haematol; 2006 Jun;28(3):154-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylenetetrahydrofolate reductase A1298C genotypes are associated with the risks of acute lymphoblastic leukaemia and chronic myelogenous leukaemia in the Korean population.
  • We investigated the association between MTHFR polymorphisms and the risks of acute and chronic leukaemias.
  • They were acute lymphoblastic leukaemia (ALL, n = 89), acute myeloid leukaemia (AML, n = 55), biphenotypic acute leukaemia (n = 12), chronic myelogenous leukaemia (CML, n = 40), and normal controls (n = 200).
  • C677T genotypes were not associated with the risk of each disease.
  • [MeSH-major] Folic Acid / metabolism. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myeloid, Acute / genetics. Methylenetetrahydrofolate Reductase (NADPH2) / genetics. Polymorphism, Genetic / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16706930.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2)
  •  go-up   go-down


50. Barthwal R, Sharma U, Srivastava N, Jain M, Awasthi P, Kaur M, Barthwal SK, Govil G: Structure of daunomycin complexed to d-TGATCA by two-dimensional nuclear magnetic resonance spectroscopy. Eur J Med Chem; 2006 Jan;41(1):27-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The anthracycline antibiotic daunomycin, having four fused rings and an amino sugar, is being used in the treatment of acute leukemia.

  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293348.001).
  • [ISSN] 0223-5234
  • [Journal-full-title] European journal of medicinal chemistry
  • [ISO-abbreviation] Eur J Med Chem
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Protons; 9007-49-2 / DNA; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


51. Kim SR, Kim HJ, Kim SH: [Clinical utility of fluorescence in-situ hybridization profile test in detecting genetic aberrations in acute leukemia]. Korean J Lab Med; 2009 Oct;29(5):371-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical utility of fluorescence in-situ hybridization profile test in detecting genetic aberrations in acute leukemia].
  • BACKGROUND: Cytogenetic abnormalities are one of the most reliable prognostic factors in acute leukemia.
  • The objective of this study was to investigate the utility of FISH profile analyses in the initial diagnosis of acute leukemia.
  • METHODS: Two hundred and forty one de novo acute leukemia patients diagnosed from January, 2002 to November, 2007 were included.
  • For acute lymphoblastic leukemia profile test, FISH probes for BCR/ABL, TEL/AML1, MLL gene rearrangement and CDKN2A deletion were used.
  • For acute myeloid leukemia profile test, probes for AML1/ETO, MLL and CBFbeta gene rearrangement were used.
  • RESULTS: ALL FISH profile tests revealed additional genetic aberrations not detected by chromosome analysis in 48.6% (67/138) of cases, including those with normal karyotypes or no mitotic cells (37%, 51/138).
  • CONCLUSIONS: FISH analysis as a profile test detected additional genetic aberrations in a significant proportion of acute leukemia, and was effective especially in detecting cryptic translocations, submicroscopic deletions and complex karyotypes.
  • Our study supports the need to incorporate FISH profile test at initial work up in acute leukemia.
  • [MeSH-major] Chromosome Aberrations. In Situ Hybridization, Fluorescence / methods. Leukemia, Myeloid, Acute / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Core Binding Factor Alpha 2 Subunit / genetics. Core Binding Factor beta Subunit / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Female. Humans. Infant. Infant, Newborn. Karyotyping. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein / genetics. Proto-Oncogene Proteins c-bcr / genetics

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19893343.001).
  • [ISSN] 1598-6535
  • [Journal-full-title] The Korean journal of laboratory medicine
  • [ISO-abbreviation] Korean J Lab Med
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Core Binding Factor Alpha 2 Subunit; 0 / Core Binding Factor beta Subunit; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RUNX1 protein, human; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; EC 2.7.11.1 / Proto-Oncogene Proteins c-bcr
  •  go-up   go-down


52. Lin YF, Lairson DR, Chan W, Du XL, Leung KS, Kennedy-Nasser AA, Martinez CA, Gottschalk SM, Bollard CM, Heslop HE, Brenner MK, Krance RA: The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia. Biol Blood Marrow Transplant; 2010 Sep;16(9):1272-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemia.
  • In a retrospective study, we evaluated the cost and cost-effectiveness of allogeneic peripheral blood stem cell transplantation (PBSCT) (n = 30) compared with bone marrow transplantation (BMT) (n = 110) in children with acute leukemia after 1 year of follow-up.
  • Treatment success was defined as disease-free survival at 1 year posttransplantation.
  • For patients at standard risk for disease, the treatment success rate was 57.1% for PBSCT recipients and 80.3% for BMT recipients (P = not significant [NS]).
  • The average total cost per treatment success at 1 year in the standard-risk disease group was $512,294 for PBSCT recipients and $352,885 for BMT recipients (P = NS).
  • For patients with high-risk disease, the treatment success rate was 18.8% for PBSCT recipients and 23.5% for BMT recipients (P = NS).
  • Point estimates of the incremental cost-effectiveness ratio (ICER) indicate that in patients with standard-risk disease, allogeneic BMT had lower costs and greater effectiveness than PBSCT (ICER, -$687,108; 95% confidence interval [CI], $2.4 million to dominated).
  • For patients with high-risk disease, BMT was more effective and more costly, and it had an ICER of $1.69 million (95% CI, $29.7 million to dominated) per additional treatment success.
  • The comparative economic evaluation provides support for BMT in standard-risk patients, but much uncertainty precludes a clear advantage of either treatment option in patients with high-risk disease.

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):29-37 [12691140.001]
  • [Cites] Bone Marrow Transplant. 2002 Aug;30(4):243-51 [12203141.001]
  • [Cites] Med Decis Making. 1985 Summer;5(2):157-77 [3831638.001]
  • [Cites] Comput Biomed Res. 1986 Jun;19(3):254-65 [3709122.001]
  • [Cites] N Engl J Med. 1989 Sep 21;321(12):807-12 [2505077.001]
  • [Cites] N Engl J Med. 1991 Apr 11;324(15):1005-11 [1848679.001]
  • [Cites] N Z Med J. 1991 Jul 24;104(916):303-5 [1906588.001]
  • [Cites] N Engl J Med. 1991 Dec 5;325(23):1601-7 [1658652.001]
  • [Cites] Bone Marrow Transplant. 1992 Apr;9(4):277-84 [1350938.001]
  • [Cites] Bone Marrow Transplant. 1993 Nov;12(5):469-75 [7905331.001]
  • [Cites] Lancet. 1995 Jan 7;345(8941):9-13 [7799740.001]
  • [Cites] Annu Rev Med. 1995;46:169-79 [7598453.001]
  • [Cites] Blood. 1995 Aug 1;86(3):1228-34 [7620176.001]
  • [Cites] Bone Marrow Transplant. 1995 Sep;16(3):463-70 [8535321.001]
  • [Cites] Lancet. 1996 Feb 10;347(8998):353-7 [8598700.001]
  • [Cites] Nat Med. 1996 May;2(5):551-5 [8616714.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1413-20 [8622054.001]
  • [Cites] Blood. 1996 Nov 1;88(9):3634-41 [8896434.001]
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(3):275-81 [9028558.001]
  • [Cites] Lancet. 1997 Sep 13;350(9080):767-71 [9297996.001]
  • [Cites] Blood. 1998 Dec 1;92(11):4047-52 [9834208.001]
  • [Cites] Bone Marrow Transplant. 1998 Dec;22(12):1199-205 [9894724.001]
  • [Cites] Bone Marrow Transplant. 1999 Sep;24(5):555-60 [10482942.001]
  • [Cites] Value Health. 2007 Jul-Aug;10(4):247-55 [17645679.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 May;15(5):564-73 [19361748.001]
  • [Cites] Bone Marrow Transplant. 2000 Aug;26(3):269-73 [10967564.001]
  • [Cites] Curr Opin Hematol. 2000 Nov;7(6):353-7 [11055508.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):689-92 [11360107.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(8):777-83 [11477433.001]
  • [Cites] Blood. 2001 Nov 15;98(10):2900-8 [11698269.001]
  • [Cites] Curr Opin Oncol. 2002 Mar;14(2):160-4 [11880705.001]
  • [Cites] Transplantation. 1974 Oct;18(4):295-304 [4153799.001]
  • (PMID = 20348004.001).
  • [ISSN] 1523-6536
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA125123-01; United States / NCI NIH HHS / CA / P30 CA125123; United States / NCI NIH HHS / CA / P30 CA 125123; United States / NCI NIH HHS / CA / P30 CA125123-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS207886; NLM/ PMC2919628
  •  go-up   go-down


53. Williams DC Jr, Massey GV, Russell EC, Riley RS, Ben-Ezra J: Translocation-positive acute myeloid leukemia associated with valproic acid therapy. Pediatr Blood Cancer; 2008 Mar;50(3):641-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Translocation-positive acute myeloid leukemia associated with valproic acid therapy.
  • Valproic acid is an effective anti-epileptic medication often used for long-term control of seizure disorders that has been implicated in hematological toxicities, including rare reports of myelodysplasia and acute leukemia.
  • Here, we report a case of valproic acid-related leukemia-like syndrome with a t(8;16) chromosomal translocation.
  • [MeSH-major] Anticonvulsants / adverse effects. Chromosomes, Human, Pair 16 / ultrastructure. Chromosomes, Human, Pair 8 / ultrastructure. Leukemia, Myeloid / chemically induced. Translocation, Genetic. Valproic Acid / adverse effects
  • [MeSH-minor] Acute Disease. Cell Differentiation. Cell Division / drug effects. Child, Preschool. Clone Cells / drug effects. Clone Cells / ultrastructure. Cocarcinogenesis. Drug Therapy, Combination. Epilepsy, Absence / drug therapy. Female. Humans. Isoxazoles / administration & dosage. Isoxazoles / therapeutic use. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / ultrastructure. Oncogene Proteins, Fusion / genetics. Phenobarbital / administration & dosage. Phenobarbital / therapeutic use. Piracetam / administration & dosage. Piracetam / analogs & derivatives. Piracetam / therapeutic use. Triazines / administration & dosage. Triazines / therapeutic use

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Phenobarbital .
  • Hazardous Substances Data Bank. ZONISAMIDE .
  • Hazardous Substances Data Bank. PIRACETAM .
  • Hazardous Substances Data Bank. LAMOTRIGINE .
  • Hazardous Substances Data Bank. VALPROIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17262798.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticonvulsants; 0 / CBP-MOZ fusion protein, human; 0 / Isoxazoles; 0 / Oncogene Proteins, Fusion; 0 / Triazines; 230447L0GL / etiracetam; 459384H98V / zonisamide; 614OI1Z5WI / Valproic Acid; U3H27498KS / lamotrigine; YQE403BP4D / Phenobarbital; ZH516LNZ10 / Piracetam
  •  go-up   go-down


54. Vega F, Medeiros LJ, Davuluri R, Cromwell CC, Alkan S, Abruzzo LV: t(8;13)-positive bilineal lymphomas: report of 6 cases. Am J Surg Pathol; 2008 Jan;32(1):14-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Approximately 75% of EMS patients present with or develop precursor T-cell lymphoblastic lymphoma, and most subsequently develop acute myeloid leukemia.
  • Here we describe the morphologic and immunophenotypic features of 6 cases of t(8;13)-positive bilineal lymphoma of mixed T-cell and myeloid lineage, 5 in lymph nodes and 1 in breast.
  • We believe that these bilineal neoplasms of mixed T-cell and myeloid lineages, which present as lymphoma, are analogous to bilineal leukemias.
  • They likely arise from an early hematopoietic cell with potential to differentiate along T-cell and myeloid pathways.
  • [MeSH-minor] Adolescent. Adult. Antigens, CD / metabolism. Cell Lineage. Child. Female. Granulocyte Precursor Cells / metabolism. Granulocyte Precursor Cells / pathology. Humans. Immunohistochemistry. Immunophenotyping. Lymphocytes / metabolism. Lymphocytes / pathology. Male. Reverse Transcriptase Polymerase Chain Reaction. Translocation, Genetic

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162765.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


55. Casillas J, Sakamoto KM: Topics in pediatric leukemia--acute lymphoblastic leukemia and late effects in long-term survivors. MedGenMed; 2005;7(1):22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topics in pediatric leukemia--acute lymphoblastic leukemia and late effects in long-term survivors.
  • [MeSH-major] Drug-Related Side Effects and Adverse Reactions. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Radiotherapy / adverse effects. Surgical Procedures, Operative / adverse effects. Survivors

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • MedlinePlus Health Information. consumer health - Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 1993;21(5):333-9 [8492747.001]
  • [Cites] Acta Paediatr. 1993 May;82(5):459-62 [8518522.001]
  • [Cites] J Pediatr. 1993 Jul;123(1):59-64 [8320626.001]
  • [Cites] Cancer. 1994 Jul 1;74(1):182-8 [8004574.001]
  • [Cites] J Clin Oncol. 2001 Apr 1;19(7):1926-34 [11283124.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Jun;86(6):2775-8 [11397886.001]
  • [Cites] Oncologist. 2001;6(3):278-85 [11423675.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3163-72 [11432882.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 12):2-7 [11552224.001]
  • [Cites] Curr Oncol Rep. 2002 Mar;4(2):131-41 [11822985.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Oct;23(7):424-30 [11878576.001]
  • [Cites] J Clin Oncol. 2002 Jul 1;20(13):2959-64 [12089225.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3136-41 [12107213.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1359-65 [12663727.001]
  • [Cites] Blood Cells Mol Dis. 2003 Jul-Aug;31(1):84-92 [12850490.001]
  • [Cites] N Engl J Med. 2003 Aug 14;349(7):640-9 [12917300.001]
  • [Cites] J Clin Oncol. 2004 Apr 1;22(7):1215-21 [15051768.001]
  • [Cites] Pediatr Radiol. 2004 May;34(5):373-8; quiz 443-4 [14963622.001]
  • [Cites] N Engl J Med. 2004 Jul 8;351(2):145-53 [15247354.001]
  • [Cites] N Engl J Med. 2004 Aug 5;351(6):601-3 [15295054.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3558-62 [15337805.001]
  • [Cites] Clin Orthop Relat Res. 1977 Jun;(125):139-44 [880755.001]
  • [Cites] Med Pediatr Oncol. 1979;7(2):141-51 [291772.001]
  • [Cites] Am J Med. 1981 Jul;71(1):47-52 [6941699.001]
  • [Cites] Skeletal Radiol. 1984;11(1):13-6 [6424236.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1984 Summer;6(2):115-21 [6589968.001]
  • [Cites] Med Pediatr Oncol. 1985;13(1):14-21 [3871501.001]
  • [Cites] Cancer. 1986 Apr 1;57(7):1287-91 [3753892.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):1981-7 [2121911.001]
  • [Cites] N Engl J Med. 1991 Mar 21;324(12):808-15 [1997853.001]
  • [Cites] Cancer. 1991 Nov 1;68(9):1913-7 [1913542.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Pediatr Neurol. 1991 Jul-Aug;7(4):237-42 [1930413.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;22(1):13-6 [1727109.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1095-102 [1318952.001]
  • [Cites] Neuropsychol Rev. 1991 Jun;2(2):147-77 [1844707.001]
  • [Cites] Arch Dis Child. 1994 Jun;70(6):476-83 [8048815.001]
  • [Cites] JAMA. 1994 Nov 9;272(18):1427-32 [7933424.001]
  • [Cites] Baillieres Clin Haematol. 1994 Jun;7(2):365-76 [7803907.001]
  • [Cites] J Bone Miner Res. 1996 Nov;11(11):1774-83 [8915786.001]
  • [Cites] J Dev Behav Pediatr. 1996 Dec;17(6):392-8 [8960568.001]
  • [Cites] Int J Obes Relat Metab Disord. 1996 Dec;20(12):1130-2 [8968860.001]
  • [Cites] J Clin Endocrinol Metab. 1998 Feb;83(2):382-95 [9467546.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):545-50 [9469339.001]
  • [Cites] Pediatr Res. 1998 May;43(5):607-13 [9585006.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 May-Jun;20(3):234-40 [9628435.001]
  • [Cites] Pediatr Rehabil. 1997 Apr-Jun;1(2):63-76 [9689241.001]
  • [Cites] Br J Cancer. 2000 Jan;82(2):255-62 [10646874.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):217-22 [10882177.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):91-5 [10918229.001]
  • [Cites] Horm Res. 2000;53(4):193-9 [11044803.001]
  • [Cites] Int J Obes Relat Metab Disord. 2000 Nov;24(11):1537-41 [11126353.001]
  • [Cites] J Pediatr Psychol. 2001 Jan-Feb;26(1):1-9 [11145727.001]
  • [Cites] Eur J Cancer. 1998 May;34(6):770-2 [9797685.001]
  • [Cites] N Engl J Med. 1999 Feb 25;340(8):653-4; author reply 655 [10049085.001]
  • [Cites] Pediatr Res. 1999 Apr;45(4 Pt 1):544-51 [10203147.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1859-65 [10223582.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Feb;50(2):163-9 [10396357.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3207-15 [10506620.001]
  • [Cites] Psychooncology. 2004 Oct;13(10):689-99 [15386645.001]
  • (PMID = 16369327.001).
  • [ISSN] 1531-0132
  • [Journal-full-title] MedGenMed : Medscape general medicine
  • [ISO-abbreviation] MedGenMed
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  • [Other-IDs] NLM/ PMC1681412
  •  go-up   go-down


56. Klingebiel T, Cornish J, Labopin M, Locatelli F, Darbyshire P, Handgretinger R, Balduzzi A, Owoc-Lempach J, Fagioli F, Or R, Peters C, Aversa F, Polge E, Dini G, Rocha V, Pediatric Diseases and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT): Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood; 2010 Apr 29;115(17):3437-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group.
  • T cell-depleted haploidentical hematopoietic stem cell transplantation (haploHSCT) is an option to treat children with very high-risk acute lymphoblastic leukemia (ALL) lacking an HLA-identical donor.
  • The 5-year leukemia-free survival (LFS) was 30%, 34%, 22%, and 0%, respectively.
  • In a multivariate analysis, haploHSCT performed in larger centers (performing > or = 231 allotransplantations in the studied period) was associated with improved LFS rate and decreased RI (adjusted P = .01 and P = .04, respectively), adjusting for different patient-, disease-, and transplant-related factors such as number of previous autotransplantations, cytomegalovirus serology status, type of T-cell depletion, and use of total body irradiation and antithymocyte globulin.
  • In conclusion, higher CD34(+) cell dose and better patient selection may improve outcomes of children with ALL who undergo a haploHSCT.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Hospitals, Pediatric. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease-Free Survival. Europe. Female. Humans. Infant. Male. Remission Induction. Risk Factors. Survival Rate. Transplantation, Homologous


57. Wong JY, Rosenthal J, Liu A, Schultheiss T, Forman S, Somlo G: Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation. Int J Radiat Oncol Biol Phys; 2009 Jan 1;73(1):273-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation.
  • PURPOSE: Total-body irradiation (TBI) has an important role in patients undergoing hematopoietic cell transplantation (HCT), but is associated with significant toxicities.
  • In a separate allogeneic HCT trial, 8 patients (5 with acute myelogenous leukemia, 1 with acute lymphoblastic leukemia, 1 with non-Hodgkin's lymphoma, and 1 with multiple myeloma) were treated with TMI plus total lymphoid irradiation plus splenic radiotherapy to 12 Gy (1.5 Gy twice daily) combined with fludarabine/melphalan.
  • Primarily Grades 1-2 acute toxicities were observed.
  • The reduced acute toxicities observed compare favorably with those seen with standard TBI.

  • Genetic Alliance. consumer health - Multiple myeloma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1986 Feb;104(2):168-75 [3511812.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Jul;13(7):1065-9 [3298176.001]
  • [Cites] J Clin Oncol. 1988 Oct;6(10):1562-8 [3049951.001]
  • [Cites] Blood. 1991 Apr 15;77(8):1660-5 [2015394.001]
  • [Cites] Blood. 1994 May 1;83(9):2723-30 [8167351.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jan 1;31(1):119-28 [7995742.001]
  • [Cites] Blood. 1998 Aug 15;92(4):1455-6 [9694737.001]
  • [Cites] Semin Radiat Oncol. 1999 Jan;9(1):108-17 [10196402.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):876-84 [16199317.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):227-34 [16169680.001]
  • [Cites] Bone Marrow Transplant. 2006 Mar;37(5):463-7 [16435013.001]
  • [Cites] Biol Blood Marrow Transplant. 2006 Mar;12(3):306-15 [16503500.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006;66(2 Suppl):S74-82 [16979445.001]
  • [Cites] Blood. 2001 Jun 1;97(11):3669-71 [11392326.001]
  • [Cites] Blood. 2002 Feb 1;99(3):731-5 [11806971.001]
  • [Cites] Bone Marrow Transplant. 2002 May;29(10):807-16 [12058230.001]
  • [Cites] Bone Marrow Transplant. 2003 Sep;32(6):543-8 [12953124.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2684-91 [12730103.001]
  • [Cites] Cancer. 1975 Sep;36(3):842-54 [1182674.001]
  • [Cites] Radiother Oncol. 1985 Dec;4(4):341-51 [3909241.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1259-67 [17336225.001]
  • (PMID = 18786784.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA033572; United States / PHS HHS / / 43904
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS83694; NLM/ PMC3896447
  •  go-up   go-down


58. Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, Isola L, Laughlin MJ, Marks DI, Nabhan S, Ruggeri A, Soiffer R, Horowitz MM, Gluckman E, Wagner JE, Center for International Blood and Marrow Transplant Research, Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation), National Cord Blood Program of the New York Blood Center: Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol; 2010 Jul;11(7):653-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis.
  • We aimed to determine the optimal role of UCB grafts in transplantation for adults with acute leukaemia, and to establish whether current graft-selection practices are appropriate.
  • METHODS: We used Cox regression to retrospectively compare leukaemia-free survival and other outcomes for UCB, PBPC, and bone marrow transplantation in patients aged 16 years or over who underwent a transplant for acute leukaemia.
  • FINDINGS: Leukaemia-free survival in patients after UCB transplantation was comparable with that after 8/8 and 7/8 allele-matched PBPC or bone-marrow transplantation.
  • Grades 2-4 acute and chronic graft-versus-host disease (GvHD) were lower in UCB recipients compared with allele-matched PBPC (HR 0.57, 95% 0.42-0.77; p=0.002 and HR 0.38, 0.27-0.53; p=0.003, respectively), while the incidence of chronic, but not acute GvHD, was lower after UCB than after 8/8 allele-matched bone-marrow transplantation (HR 0.63, 0.44-0.90; p=0.01).
  • INTERPRETATION: These data support the use of UCB for adults with acute leukaemia when there is no HLA-matched unrelated adult donor available, and when a transplant is needed urgently.


59. Agrelo R, Setien F, Espada J, Artiga MJ, Rodriguez M, Pérez-Rosado A, Sanchez-Aguilera A, Fraga MF, Piris MA, Esteller M: Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma. J Clin Oncol; 2005 Jun 10;23(17):3940-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inactivation of the lamin A/C gene by CpG island promoter hypermethylation in hematologic malignancies, and its association with poor survival in nodal diffuse large B-cell lymphoma.
  • Although the lack of expression of A-type lamins in lymphoma and leukemia has been reported, the mechanism was unknown.
  • PATIENTS AND METHODS: The promoter CpG island methylation status of the lamin A/C gene, encoding the A-type lamins, was analyzed by bisulfite genomic sequencing and methylation-specific polymerase chain reaction in human cancer cell lines (n = 74; from 17 tumor types), and primary leukemias (n = 60) and lymphomas (n = 80).
  • RESULTS: seven (50%) of 14 leukemia- and five (42%) of 13 lymphoma cell lines.
  • In primary malignancies, lamin A/C hypermethylation was present in 18% (nine of 50) of acute lymphoblastic leukemias and 34% (14 of 41) of nodal diffuse large B-cell lymphomas.
  • The presence of lamin A/C hypermethylation in nodal diffuse large B-cell lymphomas correlated strongly with a decrease in failure-free survival (Kaplan-Meier, P = .0001) and overall survival (Kaplan-Meier, P = .0005).
  • CONCLUSION: Epigenetic silencing of the lamin A/C gene by CpG island promoter hypermethylation is responsible for the loss of expression of A-type lamins in leukemias and lymphomas.
  • The finding that lamin A/C hypermethylation is associated with poor outcome in diffuse large B-cell lymphomas suggests important clinical implications.
  • [MeSH-major] CpG Islands. DNA Methylation. Gene Silencing. Lamin Type A / genetics. Lymphoma, B-Cell / genetics. Lymphoma, Large B-Cell, Diffuse / genetics. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15867203.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Lamin Type A; 0 / lamin C; M801H13NRU / Azacitidine
  •  go-up   go-down


60. ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, Huls G, Fey G, Helfrich W: A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia; 2009 Aug;23(8):1389-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • GO has improved the treatment outcome for a subgroup of acute myeloid leukemia (AML) patients, but its use is associated with severe myelosuppression and hepatotoxicity.
  • Here, we report on a novel anti-leukemia agent, designated scFvCD33:sTRAIL, in which an anti-CD33 single chain fragment of variable regions (scFv) antibody fragment is genetically linked to soluble tumor necrosis factor-related apoptosis-inducing ligand (sTRAIL).
  • The CD33-restricted anti-leukemia activity of scFvCD33:sTRAIL remained stable during prolonged storage at 37 degrees C, whereas GO showed a rapid increase in CD33-independent cytotoxicity.
  • Moreover, scFvCD33:sTRAIL showed potent anti-leukemia activity towards CD33+ CML cells when treatment was combined with the Bcr-Abl tyrosine kinase inhibitor, Gleevec.
  • Taken together, scFvCD33:sTRAIL is superior to GO in terms of tumor selectivity, activity and stability, warranting its further development for the treatment of CD33-positive leukemias.
  • [MeSH-minor] Acute Disease. Aminoglycosides / pharmacology. Antibodies, Monoclonal / pharmacology. Antibodies, Monoclonal, Humanized. Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Apoptosis / drug effects. Bystander Effect. Cells, Cultured / drug effects. Drug Delivery Systems. Drug Screening Assays, Antitumor. Drug Stability. Enzyme Activation / drug effects. Humans. Leukemia, Myeloid / pathology. Leukocytes, Mononuclear / drug effects. Neoplasm Proteins / metabolism. Sialic Acid Binding Ig-like Lectin 3. Single-Chain Antibodies. Tumor Cells, Cultured / drug effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19262596.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoglycosides; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / Antineoplastic Agents; 0 / CD33 protein, human; 0 / Neoplasm Proteins; 0 / Recombinant Fusion Proteins; 0 / Sialic Acid Binding Ig-like Lectin 3; 0 / Single-Chain Antibodies; 0 / gemtuzumab; 0 / scFvCD33-sTRAIL protein
  •  go-up   go-down


61. Adjouadi M, Ayala M, Cabrerizo M, Zong N, Lizarraga G, Rossman M: Classification of leukemia blood samples using neural networks. Ann Biomed Eng; 2010 Apr;38(4):1473-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of leukemia blood samples using neural networks.
  • Pattern recognition applied to blood samples for diagnosing leukemia remains an extremely difficult task which frequently leads to misclassification errors due in large part to the inherent problem of data overlap.
  • A novel artificial neural network (ANN) algorithm is proposed for optimizing the classification of multidimensional data, focusing on acute leukemia samples.
  • The programming tool established around the ANN architecture focuses on the classification of normal vs. abnormal blood samples, namely acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML).
  • With this type of accuracy, this programming tool provides information to medical doctors in the form of diagnostic references for the specific disease states that are considered for this study.
  • The results obtained prove that a neural network classifier can perform remarkably well for this type of flow-cytometry data.
  • [MeSH-major] Algorithms. Blood Cell Count / methods. Diagnosis, Computer-Assisted / methods. Flow Cytometry / methods. Leukemia / blood. Leukemia / pathology. Neural Networks (Computer). Pattern Recognition, Automated / methods

  • MedlinePlus Health Information. consumer health - Blood Count Tests.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20013155.001).
  • [ISSN] 1573-9686
  • [Journal-full-title] Annals of biomedical engineering
  • [ISO-abbreviation] Ann Biomed Eng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


62. Vannucchi AM: Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia. Intern Emerg Med; 2010 Jun;5(3):177-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While life expectancy may not be significantly shortened, arterial and venous thrombosis constitute the major causes of morbidity and mortality, together with disease evolution to myelofibrosis or transformation to acute leukemia.


63. Bonifaz A, Macias B, Paredes-Farrera F, Arias P, Ponce RM, Araiza J: Palatal zygomycosis: experience of 21 cases. Oral Dis; 2008 Sep;14(6):569-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The associated pre-disposing factors were: ketoacidotic diabetes (five type-1 and 15 type-2), and acute leukaemia in one patient.
  • CONCLUSION: Zygomycosis with palatal involvement occurs in around 18% of cases, usually associated with RC modalities; it has an acute and generally lethal course.
  • [MeSH-major] Mouth Diseases / microbiology. Palate / microbiology. Zygomycosis / diagnosis
  • [MeSH-minor] Absidia / isolation & purification. Adolescent. Adult. Aged. Amphotericin B / administration & dosage. Amphotericin B / therapeutic use. Antifungal Agents / administration & dosage. Antifungal Agents / therapeutic use. Brain Diseases / microbiology. Child. Diabetic Ketoacidosis / complications. Drug Combinations. Female. Fluconazole / administration & dosage. Fluconazole / therapeutic use. Humans. Itraconazole / administration & dosage. Itraconazole / therapeutic use. Male. Mucormycosis / diagnosis. Mucormycosis / drug therapy. Nose Diseases / microbiology. Opportunistic Infections / diagnosis. Oral Ulcer / microbiology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / complications. Retrospective Studies. Rhizopus / isolation & purification. Treatment Outcome


64. Hayashi H, Fujimaki C, Inoue K, Suzuki T, Itoh K: Genetic polymorphism of C452T (T127I) in human gamma-glutamyl hydrolase in a Japanese population. Biol Pharm Bull; 2007 Apr;30(4):839-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The frequency of C and T allele was 0.944 and 0.056, respectively.
  • Although the frequency of variant T allele in a Japanese population is not so high as compared to Caucasians, determination of C452T polymorphism of GGH may be useful for monitoring of efficacy and side-effects of MTX for treatment of diseases such as rheumatoid arthritis or childhood acute leukemia.

  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827858515 for PMID:17409534 [PharmGKB] .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409534.001).
  • [ISSN] 0918-6158
  • [Journal-full-title] Biological & pharmaceutical bulletin
  • [ISO-abbreviation] Biol. Pharm. Bull.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 3.4.19.9 / gamma-Glutamyl Hydrolase
  •  go-up   go-down


65. Matsuda A, Germing U, Jinnai I, Misumi M, Kuendgen A, Knipp S, Aivado M, Iwanaga M, Miyazaki Y, Tsushima H, Sakai M, Bessho M, Tomonaga M: Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood; 2005 Oct 15;106(8):2633-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the first step, we analyzed agreement of morphologic diagnosis between Japanese and German hematologists.
  • Japanese patients had a significantly lower cumulative risk of acute leukemia evolution than did German patients.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Asian Continental Ancestry Group / ethnology. Child. Disease Susceptibility. Female. Germany / ethnology. Humans. Leukemia, Lymphoid / pathology. Male. Middle Aged. Prognosis. Survival Rate


66. Andersen NF, Møller J, Peterslund NA: Piperacillin-resistant Escherichia coli bacteraemia: relation to empiric therapy and clinical outcome. Scand J Infect Dis; 2005;37(2):90-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We measured the incidence of piperacillin-resistant E. coli bacteraemia among haematological and non-haematological patients, described the importance of previous antibiotic treatment for resistance development in E. coli and evaluated the impact of piperacillin resistance on the clinical outcome of E. coli bacteraemia.
  • 114 episodes of E. coli bacteraemia in 104 patients were recorded and 98 episodes in 88 patients (42 males and 46 females) with a median age of 64 y (range 19-85 y) were evaluated.
  • In 81.6% of the episodes the patients had a haematological disorder, dominated by acute leukaemia (41.3%), chronic leukaemia (16.3%) and lymphoma (10%).
  • The proportion of piperacillin-resistant E. coli was higher among haematological patients than non-haematological patients (25% vs 0%, p=0.02) and resistance was associated with piperacillin therapy during the previous month (p=0.05).

  • MedlinePlus Health Information. consumer health - Antibiotic Resistance.
  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - E. Coli Infections.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. NETILMICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15764199.001).
  • [ISSN] 0036-5548
  • [Journal-full-title] Scandinavian journal of infectious diseases
  • [ISO-abbreviation] Scand. J. Infect. Dis.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 4O5J85GJJB / Netilmicin; X00B0D5O0E / Piperacillin
  •  go-up   go-down


67. de Lemos ML, Hamata L, Jennings S, Leduc T: Interaction between mercaptopurine and milk. J Oncol Pharm Pract; 2007 Dec;13(4):237-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mercaptopurine is a purine analog used for acute lymphoblatic leukemia and chronic myelogenous leukemias.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18045784.001).
  • [ISSN] 1078-1552
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; E7WED276I5 / 6-Mercaptopurine; EC 1.17.3.2 / Xanthine Oxidase
  •  go-up   go-down


68. Hamid GA, Shukry SA: Patterns of pancytopenia in Yemen. Turk J Haematol; 2008 Jun 5;25(2):71-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Yemen'de pansitopeni nedenleri.
  • RESULTS: The most common causes of pancytopenia were malaria and hypersplenism in > 45% of patients, followed by megaloblastic anemia in 14.7%, and aplastic anemia and acute leukemia in 13.3% each.
  • CONCLUSIONS: Hypersplenism and malaria were the most common causes of pancytopenia followed by megaloblastic anemia, aplastic anemia and acute leukemia.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27264442.001).
  • [ISSN] 1300-7777
  • [Journal-full-title] Turkish journal of haematology : official journal of Turkish Society of Haematology
  • [ISO-abbreviation] Turk J Haematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


69. Hashii Y, Okuda T, Ohta H, Ozono K, Hara J: Pediatric myeloid/NK cell precursor lymphoma/leukemia expressing T/NK immunophenotype markers. Int J Hematol; 2010 Apr;91(3):525-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric myeloid/NK cell precursor lymphoma/leukemia expressing T/NK immunophenotype markers.
  • Myeloid/NK cell precursor lymphoma/leukemia has been suggested to be of precursor NK origin.
  • We report a 1-year-old boy with myeloid/NK cell precursor lymphoma/leukemia who presented with a skin nodule.
  • He received acute myeloid leukemia-oriented combination chemotherapy.
  • Being refractory to chemotherapy, he underwent stem cell transplantation from his father.
  • Although myeloid/NK cell precursor acute leukemia is characterized by CD7(+), CD56(+), CD3(-), CD34(+) and myeloid antigen(+) phenotype, the blast cells of our patients lacked CD34 and CD7 expression while expressing myeloid antigens.
  • After acute myeloid leukemia-oriented combination chemotherapy, his blasts acquired stable CD3 expression and TCRgammadelta rearrangement at recurrence.
  • The blast cells possessed features overlapping both myeloid/NK precursor acute leukemia and blastic NK/precursor acute lymphoma/leukemia.
  • [MeSH-major] Biomarkers, Tumor. Killer Cells, Natural / pathology. Leukemia, Myeloid / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Cell Lineage. Humans. Immunophenotyping. Infant. Male

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Haematol. 2007 Nov;139(4):532-44 [17916099.001]
  • [Cites] Int J Hematol. 2002 Feb;75(2):201-6 [11939270.001]
  • [Cites] Leuk Lymphoma. 2004 Apr;45(4):739-43 [15160949.001]
  • [Cites] Blood. 2005 Nov 15;106(10):3567-74 [16046525.001]
  • [Cites] Blood. 1997 Sep 15;90(6):2417-28 [9310493.001]
  • [Cites] Immunol Rev. 2006 Dec;214:56-72 [17100876.001]
  • [Cites] Bone Marrow Transplant. 2006 Feb;37(4):425-31 [16400344.001]
  • [Cites] Leuk Res. 1999 Jul;23(7):615-24 [10400182.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):413-8 [11231495.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2006 Apr;20(4):453-6 [16643148.001]
  • [Cites] Immunol Rev. 1998 Oct;165:75-86 [9850853.001]
  • (PMID = 20146030.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Gottfredsson M, Steingrímsdóttir H: Disseminated invasive aspergillosis in a patient with acute leukaemia. Acta Biomed; 2006;77 Suppl 2:10-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disseminated invasive aspergillosis in a patient with acute leukaemia.
  • A 46-year-old previously healthy woman was diagnosed with acute lymphoblastic leukaemia.
  • Bronchoscopy was performed and treatment was administered with liposomal amphotericin B (L-AmB, AmBisome) for two days, but was complicated by acute renal failure.
  • The patient died one week following the diagnosis of aspergillosis.
  • [MeSH-major] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Aspergillosis / complications. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Acute Kidney Injury / chemically induced. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bacteremia / complications. Bacteremia / drug therapy. Chlamydophila Infections / complications. Chlamydophila Infections / drug therapy. Chlamydophila pneumoniae. Doxorubicin / administration & dosage. Drug Resistance, Multiple, Fungal. Drug Therapy, Combination. Echinocandins. Fatal Outcome. Female. Humans. Immunocompromised Host. Liposomes. Lung Diseases, Fungal / complications. Lung Diseases, Fungal / drug therapy. Medical Futility. Methotrexate / administration & dosage. Middle Aged. Neuroaspergillosis / drug therapy. Neuroaspergillosis / etiology. Peptides, Cyclic / administration & dosage. Peptides, Cyclic / therapeutic use. Pneumonia, Bacterial / complications. Pyrimidines / therapeutic use. Streptococcal Infections / complications. Streptococcal Infections / drug therapy. Triazoles / therapeutic use. Vincristine / administration & dosage. Voriconazole

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Aspergillosis.
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Acta Biomed. 2006;77 Suppl 4:following 33
  • (PMID = 16918060.001).
  • [ISSN] 0392-4203
  • [Journal-full-title] Acta bio-medica : Atenei Parmensis
  • [ISO-abbreviation] Acta Biomed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Echinocandins; 0 / Liposomes; 0 / Peptides, Cyclic; 0 / Pyrimidines; 0 / Triazoles; 0 / liposomal amphotericin B; 5J49Q6B70F / Vincristine; 7XU7A7DROE / Amphotericin B; 80168379AG / Doxorubicin; F0XDI6ZL63 / caspofungin; JFU09I87TR / Voriconazole; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


71. Kiratli H, Balci KE, Himmetoğlu C, Uner A: Isolated extraocular muscle involvement as the ophthalmic manifestation of leukaemia. Clin Exp Ophthalmol; 2009 Aug;37(6):609-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated extraocular muscle involvement as the ophthalmic manifestation of leukaemia.
  • BACKGROUND: Clinical and imaging features of patients with orbital leukaemia primarily involving extraocular muscles were evaluated.
  • METHODS: This retrospective case series includes patients with leukaemia whose only ophthalmic manifestation was extraocular muscle enlargement.
  • Demographic data, clinical information on the systemic disease, prominent ocular signs and symptoms, computed tomography and magnetic resonance imaging characteristics, treatments applied and the outcomes were collected.
  • Acute myeloid leukaemia was the diagnosis in two patients, and chronic lymphocytic leukaemia, chronic myeloid leukaemia and biphenotypic acute leukaemia were found in one patient each, respectively.
  • In one patient who had no prior history of leukaemia, an incisional biopsy established the diagnosis.
  • CONCLUSIONS: Leukaemic infiltration of extraocular muscles is a rare and late manifestation of the advanced disease associated with relapse and there seems to be a predilection for the lateral rectus muscle.
  • [MeSH-major] Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myeloid, Acute / diagnosis. Leukemic Infiltration. Oculomotor Muscles / pathology. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Child. Child, Preschool. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Ocular Motility Disorders / diagnosis. Prognosis. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Ophthalmol. 2010 Aug;38(6):651 [20553299.001]
  • (PMID = 19702712.001).
  • [ISSN] 1442-9071
  • [Journal-full-title] Clinical & experimental ophthalmology
  • [ISO-abbreviation] Clin. Experiment. Ophthalmol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


72. Marconato L, Bonfanti U, Stefanello D, Lorenzo MR, Romanelli G, Comazzi S, Zini E: Cytosine arabinoside in addition to VCAA-based protocols for the treatment of canine lymphoma with bone marrow involvement: does it make the difference? Vet Comp Oncol; 2008 Jun;6(2):80-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cytosine arabinoside (ara-C) is a component of many protocols for the treatment of acute leukaemia and non-Hodgkin lymphomas in humans.

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19178667.001).
  • [ISSN] 1476-5829
  • [Journal-full-title] Veterinary and comparative oncology
  • [ISO-abbreviation] Vet Comp Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 3.5.1.1 / Asparaginase; VCAA protocol
  •  go-up   go-down


73. Wang C, Wang GJ, Tan YH, Li W, Liu CH, Yu L: [The methylation pattern and clinical significance of Zonula occludens-1 gene promoter in acute leukemia]. Zhonghua Nei Ke Za Zhi; 2008 Feb;47(2):111-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The methylation pattern and clinical significance of Zonula occludens-1 gene promoter in acute leukemia].
  • OBJECTIVE: To investigate the methylation status of Zonula occludens-1 (ZO-1) gene promoter and discuss its role in the pathogenesis and progression of acute leukemia (AL) as a general gene marker.
  • METHODS: The methylation pattern in promoter region of ZO-1 gene was detected with methylation specific PCR in AL cell lines HL60, Molt4 and NK92 as well as in 121 clinical bone marrow samples including 81 cases of AL and 40 non malignant cases.
  • RESULTS: The promoter region of ZO-1 gene was completely methylated in HL60, Molt4 and NK92 cells; but it was unmethylated in 40 non malignant bone marrow samples.
  • The total methylation frequency of ZO-1 gene promoter region in 81 cases of AL was 60.49% (49/81), there was significant statistic difference among the relapsed AL group (92.86%, 13/14), the newly diagnosed AL group (65.85%, 27/41) and the complete remission group (34.62%, 9/26), but no difference between the cases with acute myelocytic leukemia and acute lymphocytic leukemia.
  • CONCLUSION: The hypermethylated status of ZO-1 gene promoter region was specifically detected in human AL, it was closely correlated with the pathogenesis and progression of the disease and will become a general clinical molecular marker of leukemia.
  • [MeSH-major] DNA Methylation. Leukemia / genetics. Membrane Proteins / genetics. Phosphoproteins / genetics. Promoter Regions, Genetic / genetics
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged, 80 and over. Bone Marrow Cells / metabolism. Cell Line, Tumor. Female. HL-60 Cells. Humans. Male. Middle Aged. Polymerase Chain Reaction. Young Adult. Zonula Occludens-1 Protein

  • MedlinePlus Health Information. consumer health - Childhood Leukemia.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18683795.001).
  • [ISSN] 0578-1426
  • [Journal-full-title] Zhonghua nei ke za zhi
  • [ISO-abbreviation] Zhonghua Nei Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Membrane Proteins; 0 / Phosphoproteins; 0 / TJP1 protein, human; 0 / Zonula Occludens-1 Protein
  •  go-up   go-down


74. Qian SX, Li JY, Wu HX, Zhang R, Hong M, Xu W, Qiu HX: [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr;17(2):464-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
  • The objective of this study was to evaluate the efficacy and toxicity of the fludarabine combination with high-dose cytarabine (Ara C), idarubicin and granulocyte colony-stimulating factor (G-CSF) (IDA-FLAG regimen) in treatment of refractory/relapsed acute leukemia (AL) patients.
  • 4 patients were male aged from 32 to 44 years, consisted of 3 cases of acute myeloid leukaemia (AML) and 1 cases of acute lymphocytic leukaemia (ALL).
  • The results showed that after one course of induction therapy, 4 patients all achieved complete remission (CR), in which 2 patients were in continuous CR after a follow-up of 3 and 4 months; 1 patient relapsed after 10 months and another one patient died of thrombotic thrombocytopenic purpura at 4 months after allogeneic peripheral blood stem cell transplantation.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19379589.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down


75. Schalk E, Franke A, Koenigsmann M: [Acute myeloid leukemia with pulmonary manifestation]. Pneumologie; 2005 Sep;59(9):588-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute myeloid leukemia with pulmonary manifestation].
  • [Transliterated title] Akute myeloische Leukämie mit pulmonaler Manifestation.
  • BACKGROUND: Extramedullary manifestations of leukemias are often misinterpreted.
  • The prognosis of pulmonary manifested leukemias is poor.
  • CASE REPORT: A 57-year-old female patient was admitted to our hospital because of refractory pneumonia and the suspicion of acute leukemia.
  • The diagnosis of acute myeloid leukemia (AML, FAB M5a) was derived from bone marrow aspiration.
  • The cytologic aspect of a bronchoalveolar lavage was dominated by leukemic blasts, therefore AML with pulmonary manifestation was diagnosed.
  • In contrast to the literature the initial course of the disease in this case was favourable possibly due to the addition of prednisolone to the cytotoxic treatment.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Lung Diseases / etiology
  • [MeSH-minor] Acute Disease. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fatal Outcome. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pneumologie. 2005 Nov;59(11):782
  • (PMID = 16170731.001).
  • [ISSN] 0934-8387
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


76. Djuric M, Hillier-Kolarov V, Belic A, Jankovic L: Mucositis prevention by improved dental care in acute leukemia patients. Support Care Cancer; 2006 Feb;14(2):137-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucositis prevention by improved dental care in acute leukemia patients.
  • GOALS OF WORK: The aim of the present study was to evaluate the effects of the intensive dental care protocol in preventing oral complications in acute leukemia patients.
  • PATIENTS AND METHODS: Thirty-four patients hospitalized for induction remission therapy for acute leukemia were randomly assigned to one of two groups, whether to receive intensive dental care protocol or not.
  • [MeSH-major] Dental Care / standards. Leukemia / complications. Mucositis / etiology. Mucositis / prevention & control

  • MedlinePlus Health Information. consumer health - Dental Health.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol. 1993 Oct;76(4):441-8 [8233423.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Mar;63(3):313-6 [3495768.001]
  • [Cites] Cancer. 2004 May 1;100(9 Suppl):2026-46 [15108223.001]
  • [Cites] J Oral Pathol Med. 1989 Jan;18(1):54-8 [2746518.001]
  • [Cites] J Clin Periodontol. 1991 Feb;18(2):90-3 [2005231.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1995 May;31B(3):160-5 [7549754.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1989 Dec;68(6):711-6 [2594318.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1989 Mar;67(3):279-81 [2648241.001]
  • [Cites] Oncologist. 1998;3(6):446-451 [10388137.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1992 Oct;28B(2):103-7 [1306727.001]
  • [Cites] Eur J Cancer. 1998 Sep;34(10):1588-91 [9893633.001]
  • [Cites] J Clin Oncol. 2001 Apr 15;19(8):2201-5 [11304772.001]
  • [Cites] J Clin Periodontol. 1991 Feb;18(2):85-9 [2005230.001]
  • [Cites] J Clin Microbiol. 1988 Oct;26(10):2105-9 [3182997.001]
  • [Cites] Clin Infect Dis. 1992 Jun;14(6):1201-7 [1623076.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Apr;69(4):444-9 [2326036.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2056-63 [11597384.001]
  • [Cites] J Natl Cancer Inst Monogr. 2001;(29):31-6 [11694563.001]
  • [Cites] Nat Rev Cancer. 2004 Apr;4(4):277-84 [15057287.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Mar;69(3):331-8 [2179802.001]
  • [Cites] Oral Dis. 1997 Mar;3(1):31-8 [9456644.001]
  • [Cites] Bone Marrow Transplant. 1993 May;11(5):379-82 [8504271.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1989 Sep;68(3):279-87 [2771374.001]
  • [Cites] Cancer. 2004 May 1;100(9 Suppl):1995-2025 [15108222.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1990 Dec;70(6):720-3 [2124667.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1992 Jun;73(6):682-9 [1437036.001]
  • [Cites] J Clin Periodontol. 1991 Jul;18(6):431-5 [1890224.001]
  • [Cites] Spec Care Dentist. 1998 Sep-Oct;18(5):189-93 [10219183.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Jan;65(1):19-22 [2963246.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1994;30B(2):93-7 [8032307.001]
  • [Cites] NCI Monogr. 1990;(9):61-71 [2111469.001]
  • [Cites] J Clin Oncol. 1987 Sep;5(9):1461-8 [3625260.001]
  • (PMID = 16041502.001).
  • [ISSN] 0941-4355
  • [Journal-full-title] Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  • [ISO-abbreviation] Support Care Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


77. Eid MA, Attia M, Abdou S, El-Shazly SF, Elahwal L, Farrag W, Mahmoud L: BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis. Int J Lab Hematol; 2010 Apr;32(2):197-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] BAALC and ERG expression in acute myeloid leukemia with normal karyotype: impact on prognosis.
  • Cytogenetic aberrations are important prognostic factors in acute myeloid leukemia (AML).
  • About 45% of de novo AML lack cytogenetic abnormalities, so identification of predictive molecular markers might improve therapy.
  • We studied the prognostic impact of brain and acute leukemia, cytoplasmic (BAALC) and ETS-related gene (ERG) expression in AML with normal karyotype.
  • ERG was high in 33.3% of patients and its expression was associated with lower ages and higher white cell counts.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Leukemia, Myeloid / metabolism. Neoplasm Proteins / metabolism. Trans-Activators / metabolism

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19555438.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BAALC protein, human; 0 / ERG protein, human; 0 / Neoplasm Proteins; 0 / Trans-Activators
  •  go-up   go-down


78. Italia KY, Colah R, Mohanty D: Evaluation of F cells in sickle cell disorders by flow cytometry -- comparison with the Kleihauer-Betke's slide method. Int J Lab Hematol; 2007 Dec;29(6):409-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of F cells in sickle cell disorders by flow cytometry -- comparison with the Kleihauer-Betke's slide method.
  • Adult F cell numbers are raised in inherited haemoglobin disorders, such as beta-thalassaemia and sickle cell anaemia, hereditary persistence of foetal haemoglobin, and some acquired conditions, such as juvenile myelomonocytic leukaemia, during acute erythropoietic stress and pregnancy.
  • Techniques estimating the amount of HbF use lysates prepared from RBC, whereas those that estimate the adult F cell count use intact RBC.
  • An accurate assessment of adult F cells in sickle cell disorders is important because increased adult F cells are associated with decreased morbidity in these disorders.
  • In the present study, HbF levels were measured and adult F cell numbers were estimated in 100 blood samples (25 normal individuals, 25 sickle heterozygotes, 25 sickle homozygotes and 25 sickle beta-thalassaemia cases), using high pressure liquid chromatography for HbF levels, and flow cytometry and the Kleihauer-Betke (KB) acid elution microscope slide method for cell counts.
  • [MeSH-major] Anemia, Sickle Cell / blood. Erythrocytes, Abnormal. Fetal Hemoglobin / analysis. Flow Cytometry. beta-Thalassemia / blood
  • [MeSH-minor] Adult. Erythropoiesis. Female. Fetomaternal Transfusion / blood. Fetomaternal Transfusion / pathology. Humans. Leukemia, Myeloid, Acute / blood. Leukemia, Myeloid, Acute / pathology. Male. Pregnancy. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Sickle Cell Anemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988294.001).
  • [ISSN] 1751-5521
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 9034-63-3 / Fetal Hemoglobin
  •  go-up   go-down


79. Buchholz S, Ganser A: [Hematopoietic stem cell transplantation. Indications, foundations and perspective]. Internist (Berl); 2009 May;50(5):572-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hematopoietic stem cell transplantation. Indications, foundations and perspective].
  • The hematopoietic stem cell transplantation (HSCT) has become a standard therapy for many inherited and acquired disorders of the bone marrow and immune system.
  • In contrast, allogeneic HSCT is predominantly performed in patients with acute leukemias.
  • The selection process for allogeneic HSCT takes disease-specific as well as patient-specific factors into account.
  • Risk factors which can predict for poor response to chemotherapy can now be identified in acute myeloid as well as lymphoid leukemia, based on phenotype, cytogenetics, molecular genetics and response to therapy.
  • The increasing number of long-term survivors requires knowledge of organ-specific late toxicities including secondary malignancies.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Hematopoietic Stem Cell Transplantation / trends. Leukemia / surgery. Multiple Myeloma / surgery

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Intern Med. 1988 Jun;108(6):806-14 [3285744.001]
  • [Cites] Br J Haematol. 1987 Dec;67(4):397-406 [3322360.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5183-91 [18768435.001]
  • [Cites] Blood. 2002 Aug 1;100(3):755-60 [12130482.001]
  • [Cites] Bone Marrow Transplant. 2006 Nov;38(10):645-51 [16980994.001]
  • [Cites] Curr Opin Hematol. 2007 Mar;14(2):162-9 [17255794.001]
  • [Cites] Blood. 2008 Aug 1;112(3):903-9 [18519812.001]
  • [Cites] N Engl J Med. 1995 Jan 26;332(4):217-23 [7808487.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2816-25 [15254049.001]
  • [Cites] Blood. 2004 Jul 15;104(2):579-85 [15039286.001]
  • [Cites] Ann Hematol. 2008 Jul;87(7):551-6 [18386010.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3685-91 [11504750.001]
  • [Cites] Bone Marrow Transplant. 2008 Mar;41(5):447-53 [17968326.001]
  • [Cites] Bone Marrow Transplant. 2007 May;39(10):577-88 [17369869.001]
  • [Cites] Blood. 1999 May 15;93(10):3267-75 [10233878.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):989-95 [16633362.001]
  • [Cites] Blood. 2005 Oct 15;106(8):2912-9 [15994282.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1532-42 [12176867.001]
  • [Cites] Bone Marrow Transplant. 2002 Dec;30(12 ):899-903 [12476283.001]
  • [Cites] Blood. 1990 Feb 1;75(3):555-62 [2297567.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:123-30 [16304369.001]
  • [Cites] N Engl J Med. 2007 Mar 15;356(11):1110-20 [17360989.001]
  • [Cites] Curr Opin Hematol. 2008 Jul;15(4):279-84 [18536563.001]
  • [Cites] Br J Haematol. 2006 Oct;135(2):158-64 [16939489.001]
  • [Cites] Blood. 2003 Nov 1;102(9):3447-54 [12855572.001]
  • [Cites] Transplantation. 2006 May 27;81(10):1390-7 [16732175.001]
  • [Cites] Biol Blood Marrow Transplant. 2008 Jan;14(1):67-74 [18158963.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5511-9 [17339419.001]
  • [Cites] J Clin Oncol. 2007 Sep 20;25(27):4262-9 [17724347.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Bone Marrow Transplant. 2007 Dec;40(12):1101-14 [17680020.001]
  • [Cites] Blood. 2006 Sep 15;108(6):1809-20 [16709930.001]
  • [Cites] N Engl J Med. 2008 May 1;358(18):1909-18 [18450602.001]
  • [Cites] Bone Marrow Transplant. 2000 May;25 Suppl 2:S6-8 [10933177.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2667-74 [18621929.001]
  • [Cites] Blood. 1998 Nov 1;92(9):3098-104 [9787144.001]
  • [Cites] Blood. 2007 May 15;109(10):4119-26 [17234737.001]
  • [Cites] Blood. 1990 Dec 15;76(12):2462-5 [2265242.001]
  • [Cites] Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33 [12720215.001]
  • [Cites] Blood. 2002 Jul 1;100(1):59-66 [12070009.001]
  • (PMID = 19396412.001).
  • [ISSN] 1432-1289
  • [Journal-full-title] Der Internist
  • [ISO-abbreviation] Internist (Berl)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 40
  •  go-up   go-down


80. Borlenghi E, Cattaneo C, Capucci MA, Pan A, Quaresmini G, Franco F, Grazioli L, Carosi GP, Rossi G: Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. Ann Hematol; 2007 Mar;86(3):205-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates.
  • Invasive pulmonary aspergillosis (IPA) is a frequently fatal complication in patients with acute leukaemia.
  • Because diagnosis is still difficult, non-invasive diagnostic criteria were recently proposed by MSG/IFICG/EORTC for study purposes.
  • We have analysed their usefulness in the clinical management of acute leukaemic patients with pulmonary infiltrates.
  • AML diagnosis and the first induction cycle were significant risk factors.
  • The diagnosis of "probable" IPA was made in seven patients (14%) and was strongly supported by the significant association of characteristic radiological lesions ("major" clinical criterion) with the positivity of one microbiological criterion (P = 0.026).
  • However, in 84.6% of cases, the diagnosis of "possible IPA" aspecifically derived from the association of two conditions, a new pulmonary infiltrate with symptoms of lower respiratory tract infection ("minor clinical criterion"), together with the definition of "susceptible" host, which applied to 100% of our leukaemic patients.
  • We conclude that, according to MSG/IFICG/EORTC criteria, a high number of pulmonary infiltrates would be diagnosed as IPA, but only a diagnosis of "proven/probable" IPA should be considered reliable in the clinical management of suspected IPA.
  • [MeSH-major] Aspergillosis, Allergic Bronchopulmonary / diagnosis. Aspergillosis, Allergic Bronchopulmonary / drug therapy. Leukemia / complications. Practice Guidelines as Topic
  • [MeSH-minor] Acute Disease. Adult. Aged. Antifungal Agents / therapeutic use. Ciprofloxacin / therapeutic use. Female. Humans. Itraconazole / therapeutic use. Male. Middle Aged. Models, Theoretical. Ofloxacin / therapeutic use. Reproducibility of Results. Treatment Outcome

  • Genetic Alliance. consumer health - Aspergillosis.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • Hazardous Substances Data Bank. Ofloxacin .
  • Hazardous Substances Data Bank. Itraconazole .
  • Hazardous Substances Data Bank. CIPROFLOXACIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17119965.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antifungal Agents; 304NUG5GF4 / Itraconazole; 5E8K9I0O4U / Ciprofloxacin; A4P49JAZ9H / Ofloxacin
  •  go-up   go-down


81. Nakahara F, Sakata-Yanagimoto M, Komeno Y, Kato N, Uchida T, Haraguchi K, Kumano K, Harada Y, Harada H, Kitaura J, Ogawa S, Kurokawa M, Kitamura T, Chiba S: Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood; 2010 Apr 8;115(14):2872-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia.
  • Whereas these cells did not develop myeloproliferative neoplasms when intravenously administered to irradiated mice, the combination of Hes1 and BCR-ABL in CMPs and GMPs caused acute leukemia resembling blast crisis of chronic myelogenous leukemia (CML), resulting in rapid death of the recipient mice.
  • On the other hand, BCR-ABL alone caused CML-like disease when expressed in c-Kit-positive, Sca-1-positive, and lineage-negative hematopoietic stem cells (KSLs), but not committed progenitors CMPs or GMPs, as previously reported.
  • Intriguingly, Hes1 was highly expressed in 8 of 20 patients with CML in blast crisis, but not in the chronic phase, and dominant negative Hes1 retarded the growth of some CML cell lines expressing Hes1.
  • These results suggest that Hes1 is a key molecule in blast crisis transition in CML.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Blast Crisis / metabolism. Granulocyte-Macrophage Progenitor Cells / metabolism. Homeodomain Proteins / biosynthesis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism. Neoplastic Stem Cells / metabolism. Repressor Proteins / biosynthesis
  • [MeSH-minor] Animals. Cell Line, Transformed. Fusion Proteins, bcr-abl / biosynthesis. Fusion Proteins, bcr-abl / genetics. Interleukin-3 / genetics. Interleukin-3 / metabolism. Mice. Rats

  • MedlinePlus Health Information. consumer health - Chronic Myeloid Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Blood. 2010 Apr 8;115(14):2726-7 [20378758.001]
  • (PMID = 19861684.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Hes1 protein, rat; 0 / Homeodomain Proteins; 0 / IL3 protein, human; 0 / Interleukin-3; 0 / Repressor Proteins; 149348-15-2 / HES1 protein, human; EC 2.7.10.2 / Fusion Proteins, bcr-abl
  •  go-up   go-down


82. Vannucchi AM, Guglielmelli P, Rambaldi A, Bogani C, Barbui T: Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives. J Cell Mol Med; 2009 Aug;13(8A):1437-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), which include polycythaemia vera, essential thrombocythaemia and primary myelofibrosis, originate from a stem cell-derived clonal myeloproliferation that manifests itself with variable haematopoietic cell lineage involvement; they are characterized by a high degree of similarities and the chance to transform each to the other and to evolve into acute leukaemia.
  • Their molecular pathogenesis has been associated with recurrent acquired mutations in janus kinase 2 (JAK2) and myeloproliferative leukemia virus oncogene (MPL).
  • [MeSH-major] Epigenesis, Genetic. Leukemia / drug therapy. Leukemia / genetics. Myeloproliferative Disorders / drug therapy. Myeloproliferative Disorders / genetics

  • MedlinePlus Health Information. consumer health - Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19522842.001).
  • [ISSN] 1582-4934
  • [Journal-full-title] Journal of cellular and molecular medicine
  • [ISO-abbreviation] J. Cell. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 175
  • [Other-IDs] NLM/ PMC3828857
  •  go-up   go-down


83. Lü S, Chen Z, Yang J, Chen L, Zhou H, Xu X, Li J, Han F, Wang J: The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02. Int J Lab Hematol; 2010 Feb;32(1 Pt 1):e123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of proteasome inhibitor bortezomib on a P-gp positive leukemia cell line K562/A02.
  • The aim of this study is to clarify the efficacy of proteasome inhibitor bortezomib to multidrug resistant (MDR) acute leukemia cells.
  • We observed the effects of bortezomib on a P-glycoprotein (P-gp) positive leukemia line K562/A02.
  • The results showed that bortezomib has significant effects on P-gp positive K562/A02 cells including cytotoxicity (48 h IC(50): 171.36 nM), induction of apoptosis (31.71 +/- 1.07% apoptotic cells after 24 h treatment at 100 nM), and inhibition of proteasome chymotrypsin-like activity (relative activity to untreated controls: 20.07 +/- 0.66% at 24 h with 10 nM bortezomib).
  • Bortezomib shows a promising effect for the treatment of refractory/relapsed leukemia, but it does not improve the effect of anthracycline to MDR leukemia cells.
  • [MeSH-minor] Bortezomib. Chymotrypsin / antagonists & inhibitors. Drug Resistance, Multiple. Drug Resistance, Neoplasm / drug effects. Humans. Inhibitory Concentration 50. K562 Cells. Leukemia / drug therapy. P-Glycoprotein / metabolism

  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. CHYMOTRYPSIN .
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19254348.001).
  • [ISSN] 1751-553X
  • [Journal-full-title] International journal of laboratory hematology
  • [ISO-abbreviation] Int J Lab Hematol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / P-Glycoprotein; 0 / Pyrazines; 69G8BD63PP / Bortezomib; EC 3.4.21.1 / Chymotrypsin
  •  go-up   go-down


84. Kuo YH, Zaidi SK, Gornostaeva S, Komori T, Stein GS, Castilla LH: Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice. Blood; 2009 Apr 2;113(14):3323-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Runx2 induces acute myeloid leukemia in cooperation with Cbfbeta-SMMHC in mice.
  • The core-binding factor (CBF) is a master regulator of developmental and differentiation programs, and CBF alterations are frequently associated with acute leukemia.
  • Genetic evidence suggests that deregulation of Runx2 may cause myeloid leukemia in mice expressing the fusion oncogene Cbfb-MYH11.
  • In this study, we show that sustained expression of Runx2 modulates Cbfbeta-smooth muscle myosin heavy chain (SMMHC)-mediated myeloid leukemia development.
  • Expression of Runx2 is high in the hematopoietic stem cell compartment and decreases during myeloid differentiation.
  • Sustained Runx2 expression hinders myeloid progenitor differentiation capacity and represses expression of CBF targets Csf1R, Mpo, Cebpd, the cell cycle inhibitor Cdkn1a, and myeloid markers Cebpa and Gfi1.
  • In addition, full-length Runx2 cooperates with Cbfbeta-SMMHC in leukemia development in transplantation assays.
  • Conversely, Runx2 haplo-insufficiency delays the onset and reduces the incidence of acute myeloid leukemia.
  • Together, these results indicate that Runx2 is expressed in the stem cell compartment, interferes with differentiation and represses CBF targets in the myeloid compartment, and modulates the leukemogenic function of Cbfbeta-SMMHC in mouse leukemia.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1999 Nov 19;274(47):33580-6 [10559245.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8650-5 [11438701.001]
  • [Cites] Virology. 1993 May;194(1):314-31 [8386878.001]
  • [Cites] Mol Cell Biol. 1993 Jun;13(6):3324-39 [8497254.001]
  • [Cites] Mol Cell Biol. 1994 Aug;14(8):5558-68 [8035830.001]
  • [Cites] Mol Cell Biol. 1994 Dec;14(12):8085-95 [7969146.001]
  • [Cites] Mol Cell Biol. 1995 Apr;15(4):1974-82 [7891692.001]
  • [Cites] Immunity. 1994 Nov;1(8):661-73 [7541305.001]
  • [Cites] Science. 1995 Sep 8;269(5229):1427-9 [7660125.001]
  • [Cites] Cell. 1996 Jan 26;84(2):321-30 [8565077.001]
  • [Cites] J Gen Virol. 1996 Mar;77 ( Pt 3):443-6 [8601779.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 16;93(8):3444-9 [8622955.001]
  • [Cites] Cell. 1996 Nov 15;87(4):687-96 [8929537.001]
  • [Cites] Cell. 1996 Nov 15;87(4):697-708 [8929538.001]
  • [Cites] Cell. 1997 May 30;89(5):755-64 [9182763.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Aug 5;94(16):8646-51 [9238031.001]
  • [Cites] Blood. 1999 Mar 15;93(6):1817-24 [10068652.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14541-6 [11724967.001]
  • [Cites] J Virol. 2002 May;76(9):4364-9 [11932403.001]
  • [Cites] Leukemia. 2002 Apr;16(4):658-68 [11960347.001]
  • [Cites] Nat Genet. 2002 Sep;32(1):153-9 [12185366.001]
  • [Cites] J Immunol. 2002 Sep 15;169(6):2866-74 [12218099.001]
  • [Cites] Mol Cell Biol. 2002 Nov;22(22):7982-92 [12391164.001]
  • [Cites] Cell. 2002 Nov 27;111(5):621-33 [12464175.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7181-5 [12499254.001]
  • [Cites] Blood. 2003 Jan 15;101(2):673-80 [12393679.001]
  • [Cites] Leukemia. 2003 Jan;17(1):9-16 [12529654.001]
  • [Cites] Leukemia. 2003 Mar;17(3):547-53 [12646943.001]
  • [Cites] J Biol Chem. 2003 Aug 29;278(35):33088-96 [12807882.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2249-50 [14523475.001]
  • [Cites] EMBO J. 2004 Feb 25;23(4):790-9 [14765127.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4924-9 [15044690.001]
  • [Cites] Blood. 2004 Jul 15;104(2):307-13 [14982869.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1474-81 [15142876.001]
  • [Cites] EMBO J. 1999 May 4;18(9):2551-62 [10228168.001]
  • [Cites] Nat Genet. 1999 Oct;23(2):144-6 [10508507.001]
  • [Cites] Leukemia. 2005 Feb;19(2):197-200 [15618958.001]
  • [Cites] Nat Rev Cancer. 2005 May;5(5):376-87 [15864279.001]
  • [Cites] J Cell Biochem. 2005 Jun 1;95(3):506-17 [15838892.001]
  • [Cites] Oncogene. 2005 Jun 30;24(28):4477-85 [15856017.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2005;15(3):217-28 [16390318.001]
  • [Cites] Cancer Cell. 2006 Jan;9(1):57-68 [16413472.001]
  • [Cites] Neoplasma. 2006;53(2):150-4 [16575471.001]
  • [Cites] Nature. 2006 Aug 17;442(7104):818-22 [16862118.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Oct 15;170(2):171-4 [17011991.001]
  • [Cites] J Cell Physiol. 2006 Dec;209(3):935-42 [16972259.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11214-8 [17145866.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3189-94 [17360627.001]
  • [Cites] Blood. 2007 May 15;109(10):4392-8 [17284535.001]
  • [Cites] Cancer Res. 2007 Jun 1;67(11):5148-55 [17545593.001]
  • [Cites] Cancer Biol Ther. 2007 Jun;6(6):856-63 [17438369.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19861-6 [18077419.001]
  • [Cites] J Bone Miner Res. 2008 Mar;23(3):361-72 [17997710.001]
  • [Cites] Oncogene. 1999 Nov 25;18(50):7124-34 [10597314.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):651-6 [10617663.001]
  • [Cites] Nature. 2000 Mar 9;404(6774):193-7 [10724173.001]
  • [Cites] Haematologica. 2000 Apr;85(4):362-6 [10756360.001]
  • [Cites] J Biol Chem. 2000 Jul 14;275(28):21746-53 [10801838.001]
  • [Cites] Genes Cells. 2001 Jan;6(1):13-23 [11168593.001]
  • [Cites] Nat Genet. 1999 Nov;23(3):348-53 [10610183.001]
  • (PMID = 19179305.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / F32 CA101571; United States / NCI NIH HHS / CA / R01 CA096983; United States / NCI NIH HHS / CA / CA096983; United States / NCI NIH HHS / CA / F32CA101571
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CBFbeta-MYH11 fusion protein; 0 / Core Binding Factor Alpha 1 Subunit; 0 / Oncogene Proteins, Fusion; 0 / Runx2 protein, mouse
  • [Other-IDs] NLM/ PMC2665897
  •  go-up   go-down


85. Hatta Y, Takeuchi J, Saitoh T, Itoh T, Ishizuka H, Iriyama N, Miyajima T, Kaneita Y, Saiki M, Yasukawa K, Yasukawa R, Kura Y, Nishinarita S, Sawada U, Horie T: WT1 expression level and clinical factors in multiple myeloma. J Exp Clin Cancer Res; 2005 Dec;24(4):595-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although Wilm's Tuomor gene (WT1) was first identified as a tumor suppressor gene for Wilm's tumor, WT1 overexpression has been detected in different malignant cell types including leukemia.
  • Increased expression of WT1 in acute leukemia is potentially used as a marker of minimal residual disease.
  • The expression of standardized WT1 and corrected WT1 in myeloma was 59 to 1,600 copies/microg RNA and 0.05 to 406.3 copies/microg RNA/100 plasma cells, respectively, lower than in leukemia.
  • WT1 transcripts increased when clinical factors worsen, including the stage, amount of M protein, Hb, platelet count, blood urea nitrogen (BUN), creatinine, serum alkaline phosphatase (ALP), calcium, beta2-microglobulin, thymidine kinase activity (TK), and C-reactive protein (CRP).

  • Genetic Alliance. consumer health - Multiple myeloma.
  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16471322.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / WT1 Proteins
  •  go-up   go-down


86. Turedi A, Demir C, Dilek I: Assessment of malnutrition in adult acute leukemia cases. Asian Pac J Cancer Prev; 2010;11(3):703-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of malnutrition in adult acute leukemia cases.
  • INTRODUCTION: This study examined malnutrition in acute leukemia cases, and its association to the treatment.
  • METHODS: 54 cases, consisting of 40 patients with acute myeloblastic leukemia (AML) and 14 patients with acute lymphoblastic leukemia (ALL) were included to the study, where further 34 healthy subjects were also recruited.
  • CONCLUSIONS: Prevalence of malnutrition was seen at higher percentage in adult acute leukemia cases, which was increased during the course of treatment, and TST measurement was better in establishing malnutrition.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Malnutrition / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Malnutrition.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21039039.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


87. Hatoum HA, Mahfouz RA, Otrock ZK, Hudaib AR, Taher AT, Shamseddine AI: Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report. Am J Hematol; 2007 Jan;82(1):69-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia with T-cell receptor gamma gene rearrangement occurring in a patient with chronic lymphocytic leukemia: a case report.
  • The association of chronic lymphocytic leukemia (CLL) and acute leukemia, either lymphoid or myeloid is a rare event.
  • Our review of the medical literature revealed only 6 cases of CLL transformation to acute myeloid leukemia (AML) (M0, M1 and M2) with no other associated malignancy.
  • We report a similar case but with occurrence of AML-M4 associated with normal cytogenetic analysis and molecular testing but with positive T-cell receptor gamma gene rearrangement rather than the usual Vbeta rearrangement.
  • [MeSH-major] Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Leukemia, Myeloid, Acute / genetics. Neoplasms, Second Primary / genetics


88. Sinigaglia R, Gigante C, Bisinella G, Varotto S, Zanesco L, Turra S: Musculoskeletal manifestations in pediatric acute leukemia. J Pediatr Orthop; 2008 Jan-Feb;28(1):20-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Musculoskeletal manifestations in pediatric acute leukemia.
  • BACKGROUND: In children, acute leukemia (AL) at presentation can mimic several orthopaedic pathologies, so that a variable delay of the correct diagnosis is often reported.
  • METHODS: To define more clearly the clinical and radiological musculoskeletal manifestations of leukemia in children, 122 affected children referred from 1984 to 1999 to our Pediatric Onco-Hematologic Clinic were retrospectively reviewed.
  • Average age at diagnosis was 6.6 years (from 7 months to 17 years).
  • One hundred two (83.6%) had acute lymphoblastic leukemia, 20 (16.4%) had acute myeloid leukemia.
  • RESULTS: At presentation, complaints related to the musculoskeletal system were frequent (38.3%), including pain (34.4%), functional impairment (22.9%), limping (12.3%), swelling (10.6%), and joint effusion (5.7%).
  • At presentation, 40.2% of children had at least 1 radiographic abnormality.
  • Radiographic abnormalities (P = 0.400), type of leukemia (P = 0.291), sex (P = 0.245), and white blood cell count at presentation (P = 0.877) were not prognostic factors.
  • As early diagnosis significantly decreases morbidity and mortality of AL, the orthopaedist should suspect AL in any child with unexplained persistent skeletal pain or radiographic alterations.
  • Accurate history, general physical examination, and complete blood cell count tests should address the suspicion, which is confirmed by a peripheral and/or iliac crest bone marrow biopsy.
  • [MeSH-major] Leukemia, Myeloid, Acute / complications. Musculoskeletal Diseases / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Infant. Leukocyte Count. Male. Prevalence. Retrospective Studies. Survival Rate. Time Factors

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18157042.001).
  • [ISSN] 0271-6798
  • [Journal-full-title] Journal of pediatric orthopedics
  • [ISO-abbreviation] J Pediatr Orthop
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Peters C, Cornish JM, Parikh SH, Kurtzberg J: Stem cell source and outcome after hematopoietic stem cell transplantation (HSCT) in children and adolescents with acute leukemia. Pediatr Clin North Am; 2010 Feb;57(1):27-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell source and outcome after hematopoietic stem cell transplantation (HSCT) in children and adolescents with acute leukemia.
  • Allogeneic hematopoietic stem cell transplantation from siblings, unrelated donors or HLA mismatched family members has become an important procedure to offer a chance of cure to children and adolescents with acute leukemia at high risk of relapse and those with certain genetic diseases.
  • Bone marrow (BM) was the only stem cell source for many years.
  • Each stem cell source has different risks/benefits for patients and donors, the choice depending not only on availability, but also on HLA compatibility and urgency of the HSCT.
  • This review will analyze the advantages and limitations of each of these options, and the main criteria which can be applied when choosing the appropriate stem cell source for pediatric transplant recipients with acute leukemia.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia / surgery. Stem Cells / cytology. Tissue Donors. Tissue and Organ Harvesting / methods


90. Murati A, Gervais C, Carbuccia N, Finetti P, Cervera N, Adélaïde J, Struski S, Lippert E, Mugneret F, Tigaud I, Penther D, Bastard C, Poppe B, Speleman F, Baranger L, Luquet I, Cornillet-Lefebvre P, Nadal N, Nguyen-Khac F, Pérot C, Olschwang S, Bertucci F, Chaffanet M, Lessard M, Mozziconacci MJ, Birnbaum D, Groupe Francophone de Cytogénétique Hématologique: Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia; 2009 Jan;23(1):85-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases.
  • The t(8;16)(p11;p13) is a rare translocation involved in de novo and therapy-related myelomonocytic and monocytic acute leukemia.
  • MYST3-linked acute myeloid leukemias (AMLs) share specific clinical and biological features and a poor prognosis.
  • We have established the genome and gene expression profiles of a multicentric series of 61 M4/M5 AMLs including 18 MYST3-linked AMLs by using array comparative genome hybridization (aCGH) (n=52) and DNA microarrays (n=44), respectively.
  • These features, reminiscent of T-cell acute lymphoid leukemia (ALL), suggest the targeting of a common T-myeloid progenitor.
  • [MeSH-major] Gene Expression Profiling / methods. Genes, myb / genetics. Histone Acetyltransferases / genetics. Leukemia, Myelomonocytic, Acute / genetics

  • Genetic Alliance. consumer health - Acute Myelomonocytic Leukemia.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18818702.001).
  • [ISSN] 1476-5551
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD4; 0 / Homeodomain Proteins; 0 / Proto-Oncogene Proteins c-myb; 157907-48-7 / HoxA protein; EC 2.3.1.48 / Histone Acetyltransferases; EC 2.3.1.48 / KAT6A protein, human
  •  go-up   go-down


91. Baldwin BR, Li L, Tse KF, Small S, Collector M, Whartenby KA, Sharkis SJ, Racke F, Huso D, Small D: Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease. Leukemia; 2007 Apr;21(4):764-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease.
  • Evidence is continuing to accumulate that the FMS-like tyrosine kinase 3 (FLT3) receptor plays an important role in acute leukemias.
  • Acute myeloid leukemia patients often express constitutive active mutant forms of the receptor in their leukemic cells.
  • A t(12;13)(p13;q12) translocation between Tel and the FLT3 receptor was recently described in a patient with myeloproliferative disease (MPD).
  • Expression of the fusion protein in the transgenic mice was found in all tissues assayed including spleen, bone marrow (BM), thymus and liver.
  • Spleens also had increased dendritic and natural killer cell populations.

  • COS Scholar Universe. author profiles.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268528.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA70970; United States / NCI NIH HHS / CA / CA90668; United States / NCI NIH HHS / CA / CA91177
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


92. Li L, Piloto O, Nguyen HB, Greenberg K, Takamiya K, Racke F, Huso D, Small D: Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model. Blood; 2008 Apr 1;111(7):3849-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model.
  • Constitutive activation of FMS-like tyrosine kinase 3 (FLT3) by internal tandem duplication (ITD) mutations is one of the most common molecular alterations known in acute myeloid leukemia (AML).
  • To investigate the role FLT3/ITD mutations play in the development of leukemia, we generated a FLT3/ITD knock-in mouse model by inserting an ITD mutation into the juxtamembrane domain of murine Flt3.
  • FLT3wt/ITD mice developed myeloproliferative disease, characterized by splenomegaly, leukocytosis, and myeloid hypercellularity, which progressed to mortality by 6 to 20 months.
  • No sign of acute leukemia was observed over the lifetime of these mice.
  • In the long-term competitive repopulation assay, BM cells from FLT3wt/ITD mice outgrew the wild-type competitor cells and showed increased myeloid and reduced lymphoid expansion activity.
  • Additional cooperative events appear to be required to progress to acute leukemia.